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Abstract 
 
Atrioventricular (AV) nodal block contributes to cardiovascular disease causing over 
2,150 deaths in the United States each day. Due to the limitations of current pacemaker 
technology, there is a growing need for the development of a stem cell-based AV node bypass 
device to allow for normal cardiac function. The device must deliver electrical current from the 
atrium to the ventricle with minimal current loss and cell migration along its length. As the initial 
stage of device development, a PU/PET electrospun scaffold was designed and analyzed through 
the completion of this project. 
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Chapter 1: Introduction 
 
According to the American Heart Association, cardiovascular disease (CVD) was the 
cause of 31.9% of all deaths in the United States in 2010, with over 2,150 Americans dying from 
CVD each day [1]. There are many types of heart conditions that contribute to making 
cardiovascular disease the number one cause of death in the United States [2]. One such 
condition is known as atrioventricular (AV) nodal block. AV nodal block interferes with the 
electrical system of the heart, which when functioning properly, controls and maintains a regular 
heartbeat in order to pass blood through the chambers of the heart and throughout the rest of the 
body [3]. In AV nodal block, the sinoatrial (SA) node, located in the atrium, is fully functional. 
However, the electrical signal that is propagated from the SA node is disrupted and unable to 
pass to the ventricle via the AV node. AV nodal block significantly affects heart rate and is 
normally detected through electrocardiograms [3]. While some people are born with AV nodal 
block, others develop the condition throughout their lifetime due to heart damage caused by 
other diseases, surgical procedures, or medications [3]. AV nodal block may cause fatigue, 
dizziness, fainting and can be fatal [3]. Thus, AV nodal block requires immediate treatment [3]. 
The current standard for treating AV nodal block is the implantation of an electrical 
cardiac pacemaker. An electrical cardiac pacemaker is an impulse generator that is implanted 
into the patient’s chest. Electrodes, connected to two leads originating from the generator, are 
inserted intravenously into the heart to regulate abnormal heart rate [4]. The current cost for this 
device ranges from $35,000 to about $45,000 [5]. Despite the high cost of the device, there are 
about 300,000 pacemakers implanted each year in the United States as a means to treat abnormal 
node functions, such as AV nodal block [6].  
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There are various disadvantages associated with the use of an electrical cardiac 
pacemaker. One limitation of this device is its inability to exhibit an autonomic response when 
exposed to physiological stimuli, such as stress or exercise [7]. Electrical cardiac pacemakers 
also require regular device testing and replacement for preventative maintenance. In addition, 
complications with implantation, including infections and lead displacement, can occur [7]. 
Electromagnetic interferences from the external environment or from other devices implanted in 
the body can interfere with pacemaker functionality. Finally, electrical cardiac pacemakers come 
in one size and are not adjustable for implantation in patients of various heart sizes and age 
groups [7]. 
The goal of this project was to design a self-sustaining, biocompatible AV node bypass 
mechanism that passes electrical current from the atrium to the ventricle to treat AV nodal block 
while overcoming the limitations of the current treatment method. The bypass mechanism, or 
“AV bridge,” utilizes fibrin microthread sutures seeded with human mesenchymal stem cells 
(hMSCs) to transfer the electrical current from the atrium to the ventricle. The seeded threads are 
encapsulated by a scaffold in order to insulate the current. The cellular-based AV bridge 
overcomes the limitations associated with electrical cardiac pacemakers through its physiological 
responsiveness to stimuli such as exercise or emotional stress by utilizing the signal naturally 
generated by the SA node. The fully developed bypass mechanism should be self-sustaining, 
requiring no external power source and eliminating the need for routine testing and replacement.  
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Chapter 2: Literature Review 
 
2.1 Structure and Mechanical System of the Heart 
The human heart is a hollow structure that is located posterior to the sternum and ribs, 
and anterior to the vertebral columns as shown in Figure 1 [8]. A healthy heart is about the size 
of a clenched fist, weighing about 250-350 grams [8]. The heart wall consists of three layers: the 
pericardium, myocardium and endocardium. The pericardium is the outermost portion of the 
heart that protects the vital organ. Directly inside the pericardium layer is the myocardium, 
which makes up the majority of the heart. On a cellular level, the myocardium primarily consists 
of striated cardiac muscle composed of cardiomyocyte cells that are responsible for the 
contractile function of the heart. The innermost layer of the heart wall, the endocardium, is a 
sheet of endothelial cells that allows for smooth blood flow throughout the heart [8]. 
 
Figure 1: Heart location in relation to the rib cage and spinal column (Source: 
http://commons.wikimedia.org/wiki/File:Blausen_0467_HeartLocation.png) 
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There are four separate chambers in the heart: the right atrium, the right ventricle, the left 
atrium and the left ventricle as shown in Figure 2. The right and left chambers are separated by a 
muscular wall referred to as the septum [9]. The septum prevents the oxygenated blood within 
the left side of the heart from mixing with the deoxygenated blood within the right chambers. 
Specifically, the two atriums are separated by the interatrial septum, while the two ventricles are 
separated by the interventricular septum [8]. The atria and ventricles are separated by connective 
tissue, often referred to as the central fibrous body (CFB) or the fibrous skeleton of the heart [9]. 
This CFB functions as the insulator of electrical current and action potentials between the 
atriums and ventricles, which will be discussed in the following section.  
 
Figure 2: Diagram of the four chambers and valves of the heart (Source: http-
//www.ohsu.edu/blogs/doernbecher/files/2012/08/heart-valves) 
The system of blood flow throughout the body is managed by the cardiac cycle of the 
heart. The two atria simultaneously fill and contract, sending the blood to the ventricles. Then, 
the two ventricles simultaneously fill and contract about 0.2 seconds later, sending the blood 
through the circulation systems of the heart, which will be described below [9]. Following the 
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contraction period, often referred to as systole, the atria and ventricles experience a relaxation 
period called diastole. The cardiac cycle is controlled primarily by pressure gradients present in 
the heart that cause the heart valves to open and close, managing the flow of the blood 
throughout the heart and body [8]. 
Blood flow throughout the body is controlled by two circulation systems of the heart, the 
pulmonary and systemic circulation systems. In the pulmonary circulation system, the 
deoxygenated blood enters the right atrium through the superior and inferior vena cava and is 
sent to the right ventricle through the tricuspid valve [9]. From the right ventricle, the blood is 
then sent through the pulmonary semilunar valve into the pulmonary artery, through which the 
blood is pumped to the lungs. While in the lungs, gas exchange between the blood within the 
lung capillaries and the alveoli occur, providing the blood with oxygen and transferring the 
carbon dioxide from the blood into the alveoli. The oxygenated blood then travels through the 
pulmonary veins and into the left atrium, where the systemic circulation system begins [9]. The 
oxygenated blood travels to the left ventricle through the mitral valve, where it is then pumped 
through the aortic semilunar valve and into the aorta. The aorta splits into branches and supplies 
oxygenated blood to all organs within the body. The organs retrieve the nutrients, including 
oxygen, from the blood, thereby deoxygenating the blood. This deoxygenated blood then returns 
to the right atrium and the pulmonary circulation system begins again [9]. 
2.2 Electrical System of the Heart 
The electrical system of the heart exhibits ultimate control over the mechanical function 
of the heart. The electrical system of the heart relies greatly on pacemaker cells. Pacemaker cells 
are specialized cardiomyocytes that serve as the electrical impulse generating and conducting 
cells of the heart [10]. The contractile function of the heart is moderated by the electrical activity 
that is generated from the pacemaker cells within the SA node. The SA node, located in the 
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upper anterior of the right atrium, consists of the conducting pacemaker cells that generate the 
electrical impulse that is subsequently passed throughout the heart [11]. The electrical signal 
originates from the SA node, passes through the atrium walls, and is delivered to the AV node.  
The AV node is a “compact spindle-shaped network of cells” [12] located in the right 
atrium below and posterior to the SA node [11]. The main cells that constitute the AV node are 
pacemaker cells and transitional cells [13], [11]. Transitional cells connect the specialized 
pacemaker conducting cells of the node with the cardiomyoctes in the atrium. With smaller and 
fewer gap junctions among the transitional cells of the AV node, the electrical signal is delayed 
by the node to allow for the complete emptying and closing of the atrium and the complete 
filling of the ventricles prior to ventricular contraction [13]. This delay is typically between 100-
300 milliseconds [14], [15]. Aside from delaying electrical signal, the AV node has the ability to 
act as a backup pacemaker in the case of SA node malfunction [13]. Finally, the AV node is also 
responsible for transferring the current from the right atrium to the ventricles. The AV node is 
the only pathway for current transfer between the chambers, bypassing the insulating CFB [11]. 
In the case of AV node malfunction, electrical current is unable to propagate from the atrium to 
the ventricles via an alternative route. 
The AV node collects the electrical signal generated from the SA node via the inferior 
nodal extension, which connects the node with the right atrium walls [11]. The signal passes 
through the AV node with slight delay and enters the Bundle of His. The Bundle of His is a 
collection of heart cells that collect the current from the AV node and ultimately pass the current 
to the ventricles. The Bundle of His splits into left and right bundle branches that are covered by 
a fibrous lamina that insulates the electrical current and prevents it from exiting the branches as it 
is propagated [11]. At the end of the fibrous covering of the bundle, the left and right branches 
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are referred to as the purkinje fibers. The purkinje fibers stimulate the cardiomyocytes of the 
ventricles, causing them to contract and pump blood throughout the body [11].  
In summary, the electrical impulse that controls the heart beat is generated by the SA 
node, passed through the atrium walls to the AV node, through the Bundle of His and, finally to 
the purkinje fibers that stimulate the cardiomyocytes of the ventricles to contract. Figure 3 below 
visually depicts this process. 
 
 
Figure 3: Electrical conduction pathway of the heart  
(Source: http://weill.cornell.edu/cms/health_library/images/ei_0018.jpg) 
 
2.3 Electrical Propagation through the Heart 
As previously described, the contractions of the heart are stimulated and caused by the 
electrical current delivered to cardiomyocytes throughout the heart. On a cellular level, the cells 
able to pass the pacemaker current, also known as funny current (If), from cell to cell are what 
stimulate the heart’s contractile function [16]. The cells are also able to pass ionic currents such 
as the calcium and sodium currents. An important aspect of the propagation of electrical current 
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throughout the heart is the cells’ ability to communicate with one another. Communication 
between cells occurs through cellular connections called gap junctions. Gap junctions facilitate 
the exchange of ions between cells that allows for electrical and biochemical coupling. Gap 
junctions are formed between cells that contain the same connexin intermembrane proteins and 
are in close proximity to one another. These connexins are grouped together to form 
hemichannels that have the ability to link with other channels located on nearby cells [17]. 
Specifically, in human heart tissue, there are three types of connexin proteins, Connexin 43 
(Cx43), Connexin 40 (Cx40), and Connexin 45 (Cx45). Cx43 is located in the ventricles, atria, 
and purkinje fibers. Cx40 is found in the SA node, atria, bundle branches, and the purkinje 
fibers. Finally, Cx45 is found in the SA and AV node, as well as the purkinje fibers [14]. The 
gap junctions formed by these connexins are able to efficiently pass the If and other ionic 
currents from one cell to another, allowing for the propagation of an action potential throughout 
the heart. 
As stated above, electrical impulses are generated in the SA node, passed through the 
atrial wall to the AV node, and transferred into the ventricles. As the electrical impulse is 
propagated throughout the heart, the electrical potential of the cells is adjusted. The natural 
resting potential of a cell is approximately -90 mV [18]. When the surrounding potential reaches 
-70 mV, the cell is depolarized and the current is propagated from one cell to another. The 
change in the membrane potential is known as action potential [18]. The action potential is 
generated by the exchange of K+, Ca2+, and Na+ ions through selectively permeable ion channels 
and promotes cardiac muscle cells to contract and pump throughout the body [18].  
The action potential consists of five phases as depicted in Figure 4 below. At -70mV, 
Phase 0 of action potential occurs. During this phase, the Na+ channels initially open and the 
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positive sodium ions rush into the cell [18]. As a result, the inside of the cell becomes highly 
positive in comparison to its exterior environment. When the maximum positive voltage within 
the cell is reached, the Na+ channels close and the fast K+ channels will open in Phase 1 of action 
potential. Thus, K+ ions exit the cell, causing a decrease in the voltage within the cell. During 
Phase 2 of action potential, Ca2+ channels open and the fast K+ channels close. This creates a 
plateau in which the membrane potential does not change [18]. The steady potential prolongs the 
action potential in order to collect efficient signal needed to travel throughout the conduction 
pathway of the heart. In Phase 3, the slow K+ channels open and the Ca2+ channels close [18]. 
This phase occurs in order to decrease membrane potential until the resting potential of -90 mV 
is reached. Finally, at Phase 4, the action potential is complete and the resting potential is 
maintained [18]. Each phase of action potential contributes to the passing of the If current, 
allowing for the cardiomyocytes of the heart to contract. 
 
Figure 4: Phases of action potential generation displayed in a membrane potential versus time graph  
(Source: http://www.austincc.edu/apreview/PhysText/Cardiac.html) 
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As mentioned previously, the funny current, If, is the current that paces the heart. This 
current is voltage dependent, allows for diastolic depolarization, and controls the overall 
excitability of the heart. The If requires a potential between -40 mV and -50 mV for its activation 
[16]. After an action potential occurs, the funny current is activated, slowly increasing the 
membrane voltage towards the threshold value at which another action potential can occur [16].  
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are intermembrane 
proteins that naturally occur in heart cells that assist in the generation of an action potential and 
the funny current. The HCN channels open when hyperpolarization is needed, but close during 
depolarization [6]. This ensures that the generation of current only occurs during Phase 4 of 
action potential and not during repolarization. Any type of current, including the ionic current or 
funny current, can pass through gap junctions between cells. However, cells without HCN 
channels or the equivalent cannot generate the action potential or funny current [19].  
2.4 Heart Malfunctions: Arrhythmias and AV Nodal Block 
There are various types of heart conditions that make cardiovascular disease a common 
cause of death each year. According to the 2014 Heart Disease and Stroke Statistics update 
produced by the American Heart Association, cardiovascular disease was the cause of 31.9% of 
all deaths in the United States in the year 2010, with over 2,150 Americans dying from CVD 
each day [1]. About 34% of these deaths occurred in patients below the current average life 
expectancy of 78.7 years old [1]. Various heart diseases contribute to these most recent statistics, 
including heart arrhythmias and heart blockages. These conditions interfere with the conduction 
system of the heart and frequently lead to irregular heartbeats [20]. 
The presence of arrhythmias in the heart interferes with the regularity of heartbeat pacing 
[20]. Generally, a heart affected with an arrhythmia is unable to pump adequate blood throughout 
the body. Symptoms associated with such heart conditions are fatigue, shortness of breath, 
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dizziness, and lightheadedness. These complications can ultimately result in damage to other 
vital organs, loss of consciousness, or even death [20]. Arrhythmias may interfere with atrial or 
ventricular pacing [20]. There are several types of arrhythmias that a patient may experience, 
including tachycardia and bradycardia. Tachycardia is an increased heart rate that often results 
from myocardial infarction. Bradycardia, or slow heart rate, may also be induced post 
myocardial infarction [20]. Bradycardia produces a slow, less frequent heart rate compared to a 
normal heartbeat [22]. Electrocardiographs (ECGs) are often used as a method of diagnosis for 
patients who experience tachycardia or bradycardia. ECGs record the electrical signal of the 
heart through electrodes on the thorax of the patient.  Electrocardiographic signals of patients 
who experience ventricular tachycardias are small, with higher frequency compared to signals 
produced by hearts of normal pacing [21]. Both of these arrhythmias interfere with the regular 
pacing system of the heart and may require treatment with an electric cardiac pacemaker system 
depending on their severity [20]. ECG signals of these arrhythmias are shown below in Figure 5. 
 
Figure 5: Bradycardia and tachycardia displayed via an ECG (Source: 
https://humanphysiology2011.wikispaces.com/06.+Cardiology) 
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Heart block is another condition that affects the electrical signaling of the heart, and 
therefore may be classified as an arrhythmia. Heart block can cause permanent or temporary 
conduction disturbance and can occur in various locations throughout the heart. The blockage of 
electrical impulse may occur within the atria during intra-atrial block, within the ventricles 
during intra-ventricular block, between the SA node and the atrium during SA nodal block, or 
between the atria and the ventricle during AV nodal block [23]. AV Nodal block, which is the 
abnormal conduction through the atrioventricular node, often induces ventricular bradycardia, or 
slow heart rate as previously described [20]. In AV nodal block, the sinoatrial node is fully 
functional. However, the impulse generated by the SA node is either unable to be passed to the 
ventricles or is conducted to the ventricle with immense delay. AV nodal block can occur in 
various locations throughout the conduction system of the heart, including the AV node itself, 
the Bundle of His, or the bundle branches [23]. 
Atrioventricular nodal blocks are classified by their degree of severity. In first degree AV 
nodal block, each atrial impulse is conducted to the ventricles and the ventricles are able to 
contract at a regular rate. However, the PR interval, or conduction time through the AV node, is 
elongated [23]. In second degree AV nodal block, atrial contraction, and therefore impulse 
conduction, is disrupted, intermittently or more frequently and at regular or irregular intervals 
[23]. The PR intervals associated with second-degree blocks may be fixed or elongated, causing 
intermittent or repetitive depolarization and contraction of the atria [23]. Third-degree nodal 
block is also referred to as complete nodal block and is the most severe. There is no atrial 
impulse conducted to the ventricles. Therefore, the atria and ventricles act independently at 
different rates, typically with ventricular rate less than 40 bpm [23]. Complete nodal block may 
be caused by congenital heart defects from birth that cause malfunctions [20]. A patient suffering 
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from AV nodal block may experience fatigue, dizziness, fainting, and even death if left untreated 
[3]. 
2.5 Electronic Cardiac Pacemakers 
Currently, the only treatment of AV nodal block is the insertion of a cardiovascular 
implantable electronic device (CIED). The use of pacemakers as treatment for cardiac 
dysfunctions, including AV nodal block, is increasing worldwide, with a 55.6% increase in 
pacemaker implantation the United States from 1993-2009 [24]. The electronic pacemaker is 
commonly utilized to treat arrhythmias, conduction abnormalities, and heart failure. An 
electronic pacemaker is commonly implanted into the patient’s chest through a minimally 
invasive procedure [7]. The placement of the overall device can be seen in Figure 6 below. A 
catheter is used to pass two leads, originating from the impulse generator, through the veins and 
into the atria surrounding the sinus atrial node [7]. This method of implantation eliminates the 
need for cracking open the sternum to perform open-heart surgery. On the end of each lead is an 
electrode, which delivers an electrical impulse to the heart, thus initiating and maintaining a 
regular heart beat [7].  
 
Figure 6: Image of the location of the electronic cardiac pacemaker 
(Source: 
http://www.uihealthcare.org/uploadedImages/UIHealthcare/Content/Health_Library/UI_Content/Heart_and_Vascular_Care/pa
cemaker.jpg) 
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Statistics show that there is a 5.6% annual average malfunction rate of pacemakers, 
illustrating one of the number of problems associated with the use of these devices [25]. Another 
limitation of cardiac electrical pacemakers is lack of physiological autonomic responsiveness, 
making the device unable to alter heart pacing in response to stimuli such as exercise or stress. 
While specialized rate-adaptive pacemakers have attempted to overcome this shortcoming, 
complications still arise [7]. For example, electrical pace-making units require consistent testing 
for functionality and replacement for reasons such as battery substitution [7]. Artificial 
pacemakers may also experience electromagnetic interference from the external environment [7]. 
Since these devices are not patient specific, both children and adults receive the same size 
pacemaker, which may cause complications during implantation and performance [7]. 
2.6 Autonomic Response 
As stated above, one disadvantage of the electrical cardiac pacemaker is its inability to 
respond to the intrinsic control of the autonomic nervous system (ANS). In a fully functional 
heart, the ANS exhibits a strong influence on heart rate. Emotional and physical stimuli 
including fright, anxiety, and exercise activates the sympathetic system (SN) and induces an 
increase in heart rate [26]. In response to these stimuli, sympathetic nerve fibers release 
norepinephrine at the cardiac synapse, the location where electrical signal is transferred from the 
neuron to the cardiomyocytes [26]. Norepinephrine is a biogenic amine neurotransmitter and 
catecholamine hormone that is released and exhibits control over heart rate in response to 
emotional behavior [27]. The norepinephrine released by the nerve fibers binds to β1-adrenergic 
receptors located in the SA node. Thus, the threshold for an AP to occur is quickly reached, the 
SA node fires more rapidly, and heart rate is increased. Increased heart rate enhances contractile 
function of the heart and shortens the length of relaxation, as Ca2+ can be more readily available 
 26 
to the contractile cells of the heart. As a result, end systolic volume decreases as heart rate 
increases [26].  
Additional factors including age, gender, exercise, and body temperature also cause a 
response in heart rate. For example, resting heart rate decreases with age. The resting heart rate 
of a fetus (140-160 bpm) declines throughout ones lifespan. Additionally, the average heart rate 
in adult females (72-80 bpm) is generally higher than that of males (64-72 bpm) [26]. Exercise 
also has a large influence over heart rate. Throughout exercise, heart rate increases through the 
sympathetic nervous system as previously described. Systemic blood pressure increases during 
exercise while blood flow is directed to the active muscles of the body. The resting heart rate of 
one who is physically fit is generally lower than that of those who do not regularly perform 
physical activity [26]. Lastly, body temperature may also have an effect on heart rate. An 
increase in body temperature is accompanied by an increase in heart rate, as the metabolic rate of 
cardiac cells is enhanced. In contrast, a low body temperature decreases heart rate and metabolic 
activity of cardiac cells [26]. Electrical cardiac pacemakers are unable to respond to these 
stimuli. A cellular-based therapy in treatment of AV nodal block has the potential to act as an 
alternative treatment with autonomic response to various stimuli. 
2.7 Potential Cell Types 
There are many different cell types that could be considered for use in an AV node 
bypass mechanism. For example, the use of skeletal myoblasts has been investigated. Some 
advantages of this cell type include their high proliferation rate in vitro, their ability to remain in 
an undifferentiated state, and their ability to resist ischemic stress. Skeletal myoblasts also have a 
low risk of tumor formation and do not require treatment using immunosuppressants after 
injection into the human body [28]. However, despite all of these advantages, the major 
disadvantage of skeletal myoblasts is that they are unable to electrically couple with 
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cardiomyocytes [17]. It is vital that the cells of the AV bridge communicate with cardiomyocytes 
in order for the current to be passed from the atrium to the ventricles. 
Two other options for use in an AV bridge are embryonic stem cells (ESCs) and induced 
pluripotent stem cells (iPSCs). ESCs and iPSCs are both capable of differentiating into 
pacemaker cells. Therefore, there is no need for the transfection of pacemaker genes, such as 
HCN gene channels, to generate current and prevent current loss along the length of the bridge. 
Additionally, ESCs have been shown to function properly when injected into porcine hearts [29]. 
iPSCs have been shown to be autonomically responsive in vitro [30]. In addition, iPSCs do not to 
migrate, staying localized after delivery into the heart, which is beneficial in an AV bridge 
application [6]. However, there are limitations associated with the use of ESCs and iPSCs. For 
example, ESCs and iPSCs require the use of immunosuppressants post implantation or injection 
to prevent rejection [29], [30]. Specifically in iPSCs, gene memory could result in the inability of 
the cell to express the genes of interest [6]. Also, iPSC do not contain the necessary connexins to 
allow for coupling with cardiomyocytes [31]. Specifically with ESCs, there are many ethical 
controversies surrounding the use of embryonic stem cells. 
A final cell option for this application is human mesenchymal stem cells (hMSCs). These 
cells are typically found in bone marrow and have the ability to differentiate into multiple cell 
types [32]. These cells have been shown to be safe to use and to contain the necessary connexins 
to form gap junctions with native cardiomyocytes [35]. Gap junctions are vital for cell-to-cell 
communication, allowing for the current to be successfully passed. hMSCs are also 
biocompatible, genetically stable, and have the ability to release growth factors to promote 
healing within the heart [35]. Research has shown that hMSCs have a high proliferation rate in 
vitro, making it plausible to generate the amount of cells needed to deliver a therapeutic dose 
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[36]. However, hMSCs have a tendency to migrate from the point of insertion, causing a 
potential problem in their use for an AV node bypass mechanism [37]. 
In order to generate current and prevent current loss along the length of the bridge, 
skeletal myoblasts and hMSCs require the addition of HCN gene channels through gene therapy. 
Past research has shown that HCN channels can be successfully added to hMSCs. The 
genetically altered hMSCs were then successfully shown to propagate an action potential that 
produced a heartbeat when coupled with cardiomyocytes [38], [35]. However, HCN channels are 
not required for hMSCs to form gap junctions with one another and pass electrical current from 
cell to cell. The main advantage of using HCN transfected cells within the stem-cell based bridge 
would be to generate current to accommodate for current loss as it is passed along the length of 
the device. 
There is limited prior research indicating how the addition of the HCN channels will 
affect the proliferation of hMSCs. In one study, it was shown that in vitro, the proliferation rate 
was slow and the hMSCs only divided five times over 44 days [40]. This could be a disadvantage 
with the use of hMSCs and would require careful consideration and testing when determining the 
amount of cells needed for an AV node bypass mechanism [40]. 
2.8 Fibrin Microthreads 
Fibrin microthread scaffolds are advantageous for various therapeutic applications, and 
can be considered for use in the AV bridge. Fibrin microthread scaffolds are utilized for their 
biocompatibility, and thus illicit minimal immune response when implanted into the body [41], 
[42]. Specifically, fibrin is a natural structural protein that is present in the early stages of wound 
healing [41], [42]. Throughout natural wound healing, fibrin promotes cell migration, 
attachment, and proliferation through cell-signaling properties that attract cytokines and growth 
factors to the site of injury [41], [42]. The presence of these cytokines and growth factors then 
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enhance cellular repopulation and tissue regeneration [42]. Additionally, fibrin contains RGD 
binding sites required for cell adhesion throughout tissue regeneration [41], [43]. Single fibrin 
microthreads have limited mechanical strength, which can be increased when braided or woven 
together to form bundled microthread sutures [42], [41]. 
The U.S. Food and Drug Administration has approved the use of fibrin scaffolds for 
medical applications, including surgical adhesives [43]. These scaffolds have been used to 
prevent blood loss and promote granulation tissue formation by guiding the migration and 
proliferation of fibroblasts [42]. Bundles of fibrin microthreads have also been utilized for their 
ability to form microenvironments that are similar to those present under physiological 
conditions [44].  
The fibrin application that will be utilized to deliver hMSCs to the heart to treat AV nodal 
block are fibrin microthread sutures. Individual fibrin microthreads are self-assembled structures 
that are produced through a co-extrusion process from solutions of fibrinogen and thrombin [42]. 
The fibrinogen solution is commonly obtained from bovine plasma and dissolved in HEPES 
buffered saline [42]. The thrombin solution is also obtained from bovine plasma but diluted in 
calcium chloride solution [42]. The solutions are extruded through polyethylene tubing into a 
bath of HEPES solution [42]. During the co-extrusion process of the solutions through a 
blending applicator tip, thrombin cleaves a peptide on the fibrinogen molecule to induce fibrin 
polymerization and the assembly of microthreads [42]. The resulting threads of about 100 μm in 
cylindrical diameter remain in the HEPES bath for about 15 minutes before being air-dried under 
the tension of their own weight [45], [42]. 
After being dried, the threads can be bundled together into sutures for increased strength 
and seeded with hMSCs for delivery into the heart. Previous studies have produced fibrin 
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microthread sutures composed of 12 intertwined fibrin microthreads, resulting in about 8 cm 
long bundles [46]. These bundles were then cut into 4 cm lengths, threaded through a surgical 
suture needle and folded to produce a 2 cm long and 24 thread bundle suture [46]. Each suture 
contained about 5903 + 1966 hMSCs/cm suture length after being seeded within a rotator [46]. 
Although the degradation rate of fibrin microthreads is relatively fast when exposed to 
physiological environments, it has the potential to be adjusted through UV or chemical 
crosslinking [47]. 
Through various cell-seeding techniques, such as static and dynamic cell seeding, hMSCs 
can be seeded onto fibrin microthread sutures [48]. It has been demonstrated that hMSCs 
maintain viability and their ability to proliferate when seeded on fibrin microthreads [43]. It has 
also been observed that cells seeded onto microthread bundles align along the longitudinal axis 
and within the grooves between individual threads [47]. Physical and chemical alterations of 
microthread bundles can increase the density of hMSCs seeded. For instance, microgroves 
controlled by individual thread diameter within a bundle and patterned grooves stamped onto the 
threads can increase the surface area on which the cells can bind [41], [49]. Chemically, fibrin 
microthread sutures may be altered with additional cell adhesion molecules such as fibronectin 
and RGD peptides [42]. Due to their strong influence on cell adhesion, alignment, and 
orientation, fibrin microthreads have been used to aid in the delivery of stem cells [42]. In a 
previous study performed by Guyette, et. al., it was concluded that threads have a significantly 
higher delivery efficiency (63.6+10.6%) into the left ventricular wall compared to 
intramyocardial injection (11.8+6.2%; p < 0.05) [46].  
2.9 Hollow Tubule Fibers 
 One developing technology that has the potential to be utilized in the AV node bypass 
mechanism is the hollow tubule fiber. The use of hollow fibers is being explored for tissue 
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engineering applications including regenerative medicine at institutes such as the University of 
Bath of the United Kingdom [50]. Hollow fiber tubules have proven to be successful, cell-
scaffold constructs in regenerative applications including large bone defect augmentation and 
cell delivery to infarcted myocardial tissue [50]. In tissue engineering, there is a growing need 
for culturing cells within 3D, in vivo-like environments as opposed to flat, 2D standard tissue 
culture plates. Hollow tubules provide microenvironments for encapsulated cells that mimic in 
vivo conditions, functioning similarly to porous blood capillaries [50]. Another advantage of 
hollow tubules is the high surface area to volume ratio, increasing the amount of cells seeded and 
enhancing their ability to expand with little population variation [50].  In regenerative 
applications, different cell types may be cultured on the internal or external surface of the fiber 
[50].  
 The physical structure of hollow fiber tubules is dependent upon manufacturing 
properties that can be adjusted in relation to its intended use. For example, the permeability of 
the tubule can be altered to create a minimally resistant barrier between the cells seeded inside 
the scaffold and the external environment [50]. In addition, the structural, mechanical and 
topographical aspects are dependent upon manufacturing factors including, but not limited to, the 
polymer used to create the tubule [50]. These factors can be altered to enhance biocompatibility 
of the scaffold, cell number, and cell growth when implanted in vivo [50]. Tubules with different 
structural properties have been utilized to deliver drugs and growth factors for tissue 
regeneration [50]. 
 Despite the advantages of hollow fiber tubules, there are also some associated limitations. 
For example, seeding cells within the tubule interferes with visual inspection of the cells inside 
[50]. The material composing the tubule may be unsuitable for initial cell attachment to the 
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scaffold, thus resulting in cell expansion [50]. Currently, there is no standard operating procedure 
to ensure desired success, as operation and function is heavily dependent on the cell type utilized 
and the final application of the tubule [50]. 
2.10 Electrospinning 
 Electrospinning of natural or synthetic polymer-based materials has been proven to be an 
effective and inexpensive method for scaffold production. This process can produce nanofibers 
of diameters as small as the nano-range, where other production methods are limited in this size 
range [51]. Typically, the fibers produced range from 5 to 500 nm in diameter [52]. Electrospun 
polymeric fibers have been characterized previously using scanning electron microscopy as 
shown in Figure 7, along with atomic force microscopy, X-ray diffraction and various other 
methods [53]. These nanofibers are then woven into a larger structure, such as a scaffold.  
 
Figure 7: Scanning electron microscopy image of polymeric fibers produced via electrospinning 
 
Electrospinning is based on the self-assembly of nanofibers due to electric charges and 
forces. The basic set-up of the electrospinning process can be seen in Figure 8 below. Briefly, a 
syringe filled with the polymeric solution contains a metal electrode that is connected to a power 
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supply capable of producing high voltages. In addition, there is a collecting metallic plate, 
whether cylindrical or flat, set a specified distance away from the syringe connected to the power 
supply. Once the voltage is applied, the syringe extrudes the solution, which then develops into 
fibers. These fibers are then collected on the plate to create the desired structure or scaffold.  
 
Figure 8: Diagram of the electrospinning process [52] 
 
There are a number of advantages of the electrospinning process in scaffold development. 
First, this process is generally considered easy and simple to accomplish [52]. Secondly, 
scaffolds produced via electrospinning allow for a high surface area based on the porosity of the 
structure produced [52]. However, the control of the porosity of the scaffolds can be challenging, 
which is can be considered a drawback of this method. Third, electrospinning allows for the 
production of highly porous membranes, if desired, while also maintaining the structural 
integrity of the material [53]. Lastly, there are a number of parameters that can be controlled to 
alter the final product including spin time, voltage, solution concentration and distance between 
the syringe and collecting plate. These alterations can contribute to the control of the surface 
topography, fiber diameter and pore size [51]. 
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2.11 BioGlue®  
Bioglue® Surgical Adhesive, developed by CryoLife, is a medical adhesive solution that 
can be used to seal components of polymeric scaffold materials together. Bioglue® is composed 
of purified bovine serum albumin (BSA) and glutaraldehyde. The combination is non-toxic when 
applied within the body [54].  A bi-sectional syringe, seen in Figure 9, dispenses the two 
reagents and allows them to fully mix in the applicator tip. The controlled delivery system 
eliminates the need for manual mixing or solution preparation, as the syringe is self-contained, 
easy to use, and disposable. After extrusion, the solution polymerizes within twenty to thirty 
seconds and reaches maximum strength within two minutes [54]. Bioglue® degrades via 
proteolysis, and must be kept within a moist environment after application. This medical 
adhesive can be used as an effective method for surgical repair in place of sutures, staples or 
electrocautery. Some of the potential soft tissue applications of Bioglue® within the body 
include cardiac, vascular pulmonary, and genitourinary tissues [54].  
 
Figure 9: Bioglue Surgical Adhesive, CryoLife. 2015. Web. 2 March 2015. 
(Source: http://www.cryolife.com/products/bioglue-surgical-adhesive) 
 
2.12 Heat Sealing  
The application of heat is an alternative method for sealing one thermoplastic to another. 
Components of polymeric scaffolds can undergo heat sealing in order to shrink the material to 
seal a gap or create a closed bond. Heat sealing can be performed using a direct contact method 
or applying heat at a specific proximately to a localized area in order to weld the thermoplastics 
together. While there are various sealers available for a wide range of applications, there are two 
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main types of heat sealing. Impulse heat sealers apply a pulse of energy to an area of interest, 
immediately followed by the cooling process [55]. Impulse heat sealing is recommending for use 
of thermoplastic materials including polyethylene, polyurethane, polyvinylchloride, pilofilm, 
polyvinyl alcohol, saran, nylon, polyflex, mylar, tyvek, etc. [55].  In contrary, direct or constant 
heat sealing involves constant heat application directly at the sealing site, forming contact with 
the material. Direct heat-sealing offers consistent levels of heat with the ability to penetrate 
thicker materials [55]. Materials such as coated aluminum foil, poly cell films, gusset bags, 
coated Kraft papers, waxed paper, cellophane, etc. can be used with constant/direct heat sealing 
[55]. A soldering iron, shown in Figure 10, is one type of fine tip heat source that can be used to 
seal small, sensitive materials.  
 
Figure 10: J&L 60 Watts Soldering Iron 
(Source: http://www.amazon.com/60-Watts-Soldering-Iron-listed/dp/B0006NGZK0) 
 
2.13 Cardiac Catheter  
 With advancements in medicine and technology, minimally invasive procedures are often 
preferred by both physicians and patients. For example, a minimally invasive method used for 
accessing the heart is cardiac catheterization. A catheter may be utilized in both diagnostic and 
therapeutic applications. Recent catheterization research has focused on the delivery of cells to 
the heart wall for tissue regeneration [56]. 
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 In 2011, a group of Worcester Polytechnic Institute students pursued catheter 
advancement by delivering stem-cell seeded fibrin microthreads to the left ventricular wall. To 
do so, the team developed a novel catheter system in accordance with standard catheterization 
procedures [57]. The catheter consists of a novel needle and core design contained within a 
sheath on the distal end of the catheter [57]. The sheath is detachable and can easily be replaced 
in order for physicians to load hMSCs-seeded microthreads onto the device [57]. The sheath 
creates a physiological environment for the cell-seeded fibrin microthreads, acts as a barrier 
between the cells and the exterior environment, and promotes cell viability while loaded in the 
catheter [57]. 
The delivery mechanism of the catheter is located inside of the sheath [57]. The delivery 
mechanism consists of the outer needle and the inner core, reducing the shear forces exerted on 
the cells while being inserted to the endocardium [57]. The inner core is contained within the 
outer needle as seen in Figure 11.  Prior to delivery, the threads are draped over the inner core 
and are exposed as the inner core is pushed forward through the needle [57]. 
 
Figure 11: Delivery Mechanism of the Cardiac Catheter: Inner core and outer needle contained within the sheath [57] 
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 While inserting the threads into the heart wall, the physician has control over the catheter 
on the proximal end [57]. The outer needle is exposed as the sheath is retracted upon entering the 
left ventricle through the femoral artery [57]. The outer needle and inner core are then plunged 
into the endocardial surface [57].  The inner core and threads are then pushed forward through 
the needle and are exposed within the heart tissue [57]. Once the inner core is deployed, the 
delivery mechanism is retracted from the infarcted tissue, leaving only the fibrin threads within 
the endocardium [57]. Finally, the needle is re-sheathed once the delivery mechanism has been 
removed from the ventricular wall [57]. Once the sheath is fully covering the outer needle, the 
catheter device is fully retracted from the body through the insertion pathway [57]. Insertion of 
fibrin microthreads into the heart wall is illustrated in Figure 12. Currently, there is ongoing 
development on the present catheter design. Ideally, the distal end of the catheter will be a 
detachable component in order to allow for pre-loading of the threads onto the inner core prior to 
the time of surgery. 
 
Figure 12: Insertion mechanism (read from left to right) [57]
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Chapter 3: Project Strategy 
 
3.1 Initial Client Statement 
The original client statement provided to the team by Professor Gaudette is as follows: 
Create a biological pacemaker for human use. 
With current research being developed on a biological pacemaker, the team focused the project 
on an AV node bypass mechanism to electrically connect the atrium to the ventricle when the SA 
node is fully functional. Through thorough research, the team moved forward to develop 
objectives, constraints, functions, and specifications based on the use of fibrin microthreads 
seeded with hMSCs in order to develop an innovative bypass design. Through further discussion 
with the client and extensive background research, the team revised the initial client statement 
and began the design process of a fully developed AV nodal bypass device. 
3.2 Objectives 
Primary, secondary and tertiary objectives of the AV node bypass mechanism are 
depicted in an objectives tree located in Appendix I. Pairwise Comparison Charts (PCCs) were 
completed to rank the importance of each primary and secondary objective. The team members 
and the client individually completed the PCC to compare the primary and secondary objectives, 
found in Appendix II. Numerical results obtained by each team member were averaged and 
compared to the client’s rankings to determine the final ranking of the importance of each 
objective. The results can be seen below in Tables 1 and 2: 
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Table 1: Results of PCCs comparing the team’s average with Professor Gaudette’s 
Primary 
Team 
Average Client 
Biocompatible 6 3 
Physiologically Responsive 3.75 5 
Self-Sustainable 3.875 5 
Cost-Effective 0.375 0 
Deliverable 3.375 3 
Easy to Use 1.875 1 
Reproducible 1.5 4 
 
 
Table 2: Results of Secondary PCCs comparing the team’s average with Professor Gaudette’s 
Secondary 
Team 
Average Client 
Biocompatible     
      Immune Response 2 2 
      Disruption to Heart 0.875 1 
      Scar Formation 0.125 0 
Self-Sustainable     
      Passage of Nutrients 1.75 2 
     Outside Power Source 1.5 2 
    Withstand Cyclic Loading 
and Contractile Forces 1.25 0 
     Cell Balance 1.5 3 
Cost-Effective     
     Manufacturing Company 0 1 
     Insurance Company 2 3 
     Patient 4 1 
     Surgeon 1 2 
     Hospital 2.5 3 
Reproducible - Accuracy     
     Mechanically 2 0 
     Electrically 1 2 
     Biologically 0 1 
 
 
 40 
Through the completion of PCCs and discussion with the client, the primary objectives of 
the bypass mechanism are ranked in order of most to least importance: self-sustaining and 
physiologically responsive, biocompatible, reproducible, deliverable, easy to use, and cost-
effective.  
3.2.1 Self-Sustaining  
 Self-sustaining and physiologically responsive received the highest scores upon 
completion of the PCC, tying as the most significant primary objectives for the AV node bypass. 
Self-sustaining implies that the cellular device will be able to properly function when implanted 
inside the heart through optimal cell survival and sound structure without the need for an 
external power source. If the bypass mechanism is unable to maintain function once implanted 
into the heart, the electrical impulse will not be passed from the atrium to the ventricle and the 
device will fail. 
In contrast to the electrical cardiac pacemaker, the bypass mechanism will not require an 
external power source. Therefore, routine device testing and battery replacement will not be 
necessary to maintain the function of the bypass throughout its lifespan. Due to the absence of an 
external power source, optimal cell balance within the bridge is crucial. The net proliferation and 
cell death rates must be balanced to provide optimal current propagation. This will ensure that the 
number of cells required to pass the signal from the atrium to the ventricle at a specified speed is 
continuously present and able to improve and maintain heart function. Furthermore, the device 
should allow for the passage of nutrients to the cells to promote cell survival. If the nutrients 
cannot reach the cells, the cells will not remain viable, the current will not be propagated 
through the heart, and the device will ultimately fail. Finally, the bypass mechanism should be 
able to withstand the natural cyclic contractile stress that the heart will exert on the bridge. Thus, 
the bridge must remain structurally sound after its implantation into the heart.  
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The most important secondary objective within self-sustaining is the passing of nutrients 
to the cells. This objective is followed by cell proliferation balance and functionality without an 
outside power source, both of equal importance. The least important objective is the ability to 
withstand the cyclic loading and forces naturally produced by the heart. The ranking of 
secondary objectives supports the importance of cell survival required for device functionality. 
To promote cell viability and survival, nutrients must be passed to the cells and waste must be 
removed from the cells within the bridge. An appropriate cell balance is necessary to ensure that 
an optimal amount of current is passed through the bridge. The absence of an external power 
source is of equal importance, making the bypass mechanism an improved treatment method for 
AV nodal block compared to the electrical cardiac pacemaker. Finally, it is important that the 
device withstands the forces exerted by the heart. However, this secondary objective is of least 
importance compared with previously ranked objectives as structural stability does not promote 
current propagation if viable cells are not present within the bridge. 
3.2.2 Physiologically Responsive 
 In contrast to the electrical cardiac pacemaker, the AV node bypass mechanism should be 
physiologically responsive. The device should be able to pass a range of currents at different 
speeds in relation to the generation of current by the SA node in response to physiological 
stimuli such as exercise and stress. As one of the main objectives of the AV node bypass 
mechanism, physiological responsiveness is comparably significant to self-sustaining. Meeting 
this objective will improve current treatment methods for AV nodal block, such as the electrical 
cardiac pacemaker, adjusting heart rate according to physical and emotional stimuli. 
3.2.3 Biocompatible 
Biocompatibility involves the ability of the device to minimally interrupt natural heart 
function and ultimately avoid rejection when implanted into the body. Biocompatibility is the 
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third most important primary objective of the device and is a crucial component promoting 
optimal device function. However, there is a degree of incompatibility that will not interfere 
with device function. Therefore, minimal immune response, minimal disruption to the 
contractile system, and minimal scar formation may occur without affecting device function as 
long as the symptoms do not reach an incompatible threshold that causes the heart to fail.  
When implanted into the body, the bypass mechanism should produce minimal immune 
response, with little inflammatory reaction and cytotoxicity. In the presence of significant 
immune response, the device would be rejected, leading to failure and presenting dangerous 
conditions to the patient. It is likely that a slight immune response may occur while implanting a 
foreign object into the heart. Due to the potential severity of harmful conditions that the patient 
could ultimately be exposed to, minimal immune response is the most important biocompatible 
objective the device meets.  
Secondly, the device should minimize disruption to the natural contractile system of the 
heart. There can be a small degree of disruption to the contractile system; however, the heart 
should effectively pump blood throughout the body when the device is implanted. This is an 
important objective that allows the heart to perform normal contractile function with the 
implanted device present to assist in current propagation and regulating heartbeat.  
Finally, the bypass mechanism should produce minimal scar tissue formation and 
overgrowth of collagen. Scar tissue and collagen overgrowth may interfere with the passage of 
current from the atrium to the ventricle through the bypass mechanism and lead to malfunction 
and device failure. 
3.2.4 Reproducible 
Another major objective that needs to be considered is the reproducibility of the device. It 
is important that the device produces uniform results and properties in terms of functionality and 
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manufacturability. Reproducibility encompasses the accuracy and precision of device 
functionality. It is ranked as the fourth most important objective because in order to prevent 
failure of the device, it is not necessarily important for the device to be easily reproduced. 
However, in order to function properly, it must produce accurate results in current propagation. 
Precise functionality and properties are important to consider if the device is to be mass-
produced. It is concluded that the accuracy of the device is more important than its precision, as 
accurate properties directly relates to proper functionality in passing the current from the atrium 
to the ventricle.  
First, the device must accurately pass the necessary amount of signal at an appropriate 
velocity with required delay to promote normal contractile function of the heart. This was 
considered to be the most important secondary objective based on the primary function to pass 
the current required to pace the heart. Secondly, the cellular-based device must consistently 
interact with the biological tissue surrounding the implantation site. Finally, it is least important 
that the bypass mechanism is produced to have accurate yield strength and fatigue failure based 
on intended design values to ensure that the device will not ultimately fail. This objective is least 
important because mechanical properties do not directly affect the ability of the device to pass 
electrical current. However, these properties must be accurately reproduced for every patient to 
ensure safety and proper function of the device.  
As mentioned above, the precision of device reproducibility is important for mass 
marketing the device. If the device were to be mass-produced, the FDA and other regulatory 
agencies will require that the device have precise, standard manufacturing processes. However, 
this does not directly affect device functionality. In relation to mass-production, the 
manufacturing process of the device should utilize a consistent protocol in order to guarantee 
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that the same product is created each time. If various manufacturers cannot reproduce the 
protocol, a limited amount of effective bridges will be created and the device will therefore be 
utilized by a fewer amount of patients.   
3.2.5 Deliverable 
Another main objective that should be considered is the delivery of the device into the 
heart. Deliverable was considered to be less important that reproducible because it does not affect 
the way the device functions. The secondary objectives that relate to deliverable are minimally 
invasive, compatible with the current technology, and implantable.  It is most important that the 
delivery method be minimally invasive to result in fewer potential complications, as well as a fast 
recovery time. This is most important because it directly affects the health of the patient. The 
second most important sub-objective is compatibility with current technology, referring to the fact 
that the device should use current methods and instruments developed for the delivery of devices 
to the heart. The use of current technology will eliminate the need to develop a new tool for 
delivery and would result in sooner marketing of the device.  
3.2.6 Easy to Use 
The next primary objective to consider is that the AV bridge should be easy to use. This 
objective is not of crucial importance because it does not directly affect the function of the 
device. Ease of use is less important than deliverability because the ease of use will not affect 
the health of the patient. There are two secondary objectives under ease of use: ease of 
implantation into the heart and the ease of assessing functionality of the device after 
implantation. Easy to use encompasses both the materials utilized and method of implantation. 
The materials that compose the device must be easy for a prep team and surgeon to handle and 
implant, ideally with minimally invasive techniques. Additionally, cardiologists must be able to 
easily assess the functionality of the device after implantation through a procedure that does not 
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require additional surgery. If the functionality of the device cannot be measured by a cardiologist 
years after implantation, then it will be difficult to ensure the health of the patient. 
3.2.7 Cost-Effective 
The final and least important primary objective for the AV node bypass mechanism is 
cost-effectiveness, which implies that the price of the bypass must be comparable to that of an 
electronic cardiac pacemaker currently on the market. The device needs to be reasonably priced 
to ensure it can be marketable. If there is a large increase in price compared to that of an 
electronic pacemaker, the value of the bypass should increase so that stakeholders are willing to 
pay more for the product. If the final product is too expensive and believed to not be worth its 
price, it will not be purchased. The ability to compare the price of the device to the price of the 
gold standard will vary depending on the targeted audience. Targeted audiences examining the 
cost of the device include the manufacturing company, insurance company, patient, surgeon and 
the hospital.  
It was determined that the device should be most cost effective to the insurance company. 
The insurance company will be a primary stakeholder to the device because it will cover the cost 
of the bypass. If the insurance company does not believe the device is worth its’ cost, they will 
not cover the expense for the patient. The hospital is the second most important audience in 
terms of cost-effectiveness of the device. If the hospital does not believe the device is cost 
effective, they will not carry the product and the bypass will not be an option of treatment for the 
patient. The manufacturing company is the third most important when considering cost-
effectiveness. The main priority of the manufacturing company is to make a profit from the mass 
production of the device.  If the device is too expensive, they will not make a profit and will not 
want to manufacture the AV node bypass mechanism. The patient was ranked of little 
importance in terms of the cost effectiveness of the device. While it is important for the patient to 
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believe the device is valuable, they will not be typically paying for the cost of the device 
themselves. Finally, the cost-effectiveness to the surgeon is least important because they do not 
have much concern over the cost of the device.  
3.3 Functions and Specifications 
In order to successfully meet the aforementioned objectives of the project, specific 
functions of the developed AV node bypass system are needed. Four overall functions of the 
system were developed: 
1. Must receive, transmit and deliver current. 
2. Must minimize the loss of current transferred via the bypass system. 
3. Must minimize cell loss. 
4. Must not disrupt native heart function.  
3.3.1 Must receive, transmit and deliver current 
With a malfunctioning AV node, the electrical conduction of the heart cannot be 
collected, transmitted or delivered to the ventricles. Therefore, the bypass system first needs to 
collect the electrical current from the SA node in the atrium in order to stimulate the bypass 
system and allow for continuation of action potentials throughout the length of the bridge. The 
bridge will contain an appropriate amount of human mesenchymal stem cells, which collects and 
passes the current through gap junctions between the seeded hMSCs and the native 
cardiomyocytes. By allowing for gap junction formation between the transfected hMSCs and 
native cardiomyocytes, the current will be able to be collected and passed throughout the bridge 
through the gap junctions between the cells [6]. The presence of the HCN channels in the 
hMSCs, which couple with the native cardiomyocytes, will allow for the generation of current 
along the bridge in the case of current loss which will be discussed further in a later section. 
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The end of the bypass bridge must be connected to the cardiomyocytes in the atrium to 
collect the current and stimulate the bypass system. The bridge must then be able to transmit the 
current from a point in the atrium to a point in the ventricle. As recommended by Professor 
Gaudette, the minimal bypass distance is 2 cm in order to bypass the central fibrous body. While 
the natural conduction velocity in the AV node is about 5 cm/s, the conduction velocity of the 
bypass system should be between 25-100 cm/s, per Professor Gaudette’s request, in order to 
account for the longer distance travelled by the bridge in comparison to the natural length of the 
AV node [13]. The bypass mechanism should also account for the natural delay of a functioning 
AV node, which is approximately 100-300 ms [14], [15]. Finally, the bypass system must be able 
to successfully deliver the current to the ventricle via the gap junctions formed between the 
hMSCs and native cardiomyocytes in the right ventricle. 
3.3.2 Must minimize the loss of current transferred via the bypass system 
The electrical current propagated through the bypass device should pass primarily in the 
longitudinal direction and should be limited in loss of current in the radial direction. The loss of 
current in the radial direction would result in an inefficient conduction of the current to the 
ventricles. Therefore, the hMSCs must be encapsulated by an insulating scaffold that minimizes 
the loss of current.  
The encapsulating scaffold ends should have a pore size of approximately 2.0-2.5 μm in 
order to allow for proper exchange of nutrients through the bridge to maintain cell viability, 
while also containing the current [58]. In addition, this pore size was calculated by a previous 
Worcester Polytechnic Institute Major Qualifying Project team to be small enough to prevent 
hMSCs from migrating through as these cells have a natural affinity to migrate [37], while still 
allowing the hMSCs to form gap junctions with the native cardiomyocytes. These gap junctions 
are vital in collecting the current from the atrium and delivering the current to the ventricle.  
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As mentioned above, the use of HCN channel transfected hMSCs should allow for the 
generation of current along the bridge if coupled with native cardiomyocytes. This should aid in 
the maintenance of the current along the bridge if any current is lost in the radial direction. 
3.3.3 Must minimize cell loss 
The bypass system must minimize cell loss throughout the manufacturing, implantation 
and lifetime of the bypass bridge. Throughout these processes, the bridge needs to maintain a 
certain number of viable cells in order to efficiently pass current from the atrium to the ventricle 
once it is in place in the heart. As agreed upon with Professor Gaudette, the order of importance 
of these three processes is transplantation, lifetime, and manufacturing. It is most important to 
minimize cell loss during the transplantation of the device into the heart because this is the stage 
in which there is the highest risk of losing cells while being unable to replace them thereafter. 
The method of delivery of the bypass system will be controlled, which ultimately controls the 
cell loss during this process. Secondly, the minimization of cell loss during the lifetime of the 
design is important because the loss of cells during this process calls for additional surgery to 
replace the cells or bypass system as a whole to maintain the functionality of the device. 
However, there is less control over this process in comparison to transplantation. Finally, the 
manufacturing of the complete bypass system must be controlled to minimize cell loss. This is 
least important due to the manufacturer’s ability to replace lost cells at this point in time before 
implantation.  
3.3.4 Must not disrupt native heart function 
 Finally, the AV node bypass system must cause minimal disruption to the functionality of 
the native heart. This system must not disrupt the contractile system of the heart, must not 
interrupt the mechanical function of the heart and must not produce an immune response by the 
heart.  
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3.4 Constraints 
There are multiple identifiable constraints that were taken into account throughout the 
project design process: the overall safety of the device, the project budget, and the project time-
span.  
3.4.1 Safety  
In terms of device design, safety acted as a key constraint. The AV node bypass must be 
safe, as it cannot illicit harmful, cytotoxic effects or be rejected when implanted into the human 
body. Factors, such as the amount of current conducted along the bypass mechanism, were 
carefully considered to ensure safety of the device and ultimately maintain the health of the 
patient. The material composition and subsequent degradation byproducts produced by the 
encapsulating scaffold also required consideration. The material and chemical byproducts could 
not cause harmful effects to the patient or compromise heart function.  
3.4.2 Project Time-Span 
Another constraint is the short time period during which this project must be completed. 
Specifically, the bypass mechanism was produced during the academic school year, extending 
from August 2014 to April 2015. All product development, design testing and data collection 
was completed by mid-April in order to report and compile final results by the project 
completion deadline in April 2015.  
3.4.3 Project Budget 
The limited budget of $156 per team member, totaling $624 in total for an MQP team of 
four members, was a constraint throughout the completion of this project. The cost of the 
Goddard Hall lab fee, prototype materials, including scaffold and testing materials, and final 
design materials had to be incorporated into the $624 budget. All fees required for project design 
and testing aspects must be included within the $624 total budget.  
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3.5 Revised Client Statement 
In considering the developed objectives, constraints, functions and specifications, a 
revised client statement was developed to expand upon the original statement. This statement is 
as follows: 
Design and develop a self-sustaining, biocompatible AV node bypass mechanism that 
electrically connects the atrium to the ventricle. The bypass should be a minimum of 2 cm 
in length and have a conduction velocity between 25-100 cm/s. The bypass should make 
use of fibrin microthreads seeded with hMSCs to pass electrical current with an 
encapsulating scaffold around the threads to insulate the current. There should be a 
delay in conduction from the atrium to the ventricles similar to that of the AV node delay 
of approximately 100-300 ms. The bypass should be physiologically responsive to stimuli 
and have the mechanical stability to withstand cyclic loading of the contracting heart.  
3.6 Further Project Approach 
 Through further understanding and discussion of these developed objectives, constraints 
and functions, the team developed conceptual designs and preliminary designs through 
brainstorming activities and analysis, as will be discussed in Chapter 4. Each design was 
analyzed in order to determine parts of the device that needed to be tested in order to verify the 
functionality of the designs. These determined tests were run and allowed for the team to deem a 
final design of the AV bypass mechanism. 
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Chapter 4: Alternative Designs 
 
 Taking into consideration the aforementioned objectives, constraints, functions and 
specifications, the team developed a number of design concepts that would function as an AV 
nodal bypass mechanism. The team began this process with a brainstorming session in which 
each function was analyzed and conceptual methods of achieving them were determined. For 
example, the current could be collected from the SA node similar to how a plug collects 
electricity from a wall socket. Important ideas drawn from the brainstorming process are listed 
below in Table 3. 
Table 3: Brainstorming activity results for the first three functions 
 Idea 1 Idea 2 Idea 3 Idea 4 
Receive, 
transmit and 
deliver 
current 
Socket 
(Collect/D
eliver) 
Funnel 
(Collect/
Deliver) 
River 
(Collect/T
ransmit/D
eliver) 
Wire 
(Transmit/
Deliver) 
Minimize loss 
of current 
Wire Mesh Myelin 
Sheath 
 
 
Minimize cell 
loss 
Blood 
vessel 
diffusion 
Skin   
 
4.1 Conceptual Designs   
 To begin the design process of developing the AV nodal bridge, conceptual designs were 
developed with the brainstorming ideas shown above in mind. The conceptual designs represent 
the beginning stage of determining the optimal final design. Each of the following conceptual 
designs includes a combination of fibrin microthreads, hMSCs and an encapsulating scaffold.  
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4.1.1 Primary Conceptual Designs 
 As shown in Figure 13, the primary conceptual designs consist of three versions of the 
bridge in which the fibrin microthreads seeded with hMSCs protrude out of the ends of the 
encapsulating scaffolds. The ‘funnel’ design consists of a number of threads protruding out of 
the scaffold in a funnel formation. This was seen as beneficial in terms of collecting current from 
a number of areas in the atrium and distributing the current in a similar fashion in the ventricles. 
The bridge would be able to collect the current due to the gap junctions formed at the ends of the 
scaffold between seeded hMSCs and native cardiomyocytes. The current would be passed along 
the bridge via gap junctions between the seeded hMSCs. This is displayed in Figure 13 and 
Figure 14 of conceptual designs.  
Second, the ‘socket’ design in the center of Figure 13 imitates a plug and electrical 
socket, as the bridge similarly collects electrical current from two locations in the atrium and 
distributes to the ventricles in a similar fashion. However, there are fewer places from which the 
socket design can draw current from in comparison to the funnel.  
Third, the bundle design on the right of Figure 13 is a simple bundle of microthreads 
seeded with the hMSCs within an encapsulating scaffold.  
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Figure 13: First conceptual designs - funnel (left), socket (center) and bundle (right). 
 
Upon analyzing the primary conceptual designs, it was determined that the amount of 
fibrin microthreads and cells protruding from the scaffold would not meet the function of 
minimizing cell loss. With the purpose of the scaffold to encapsulate the cells and minimize 
migration of hMSCs, the team determined there must be minimum to no exposure of the cells to 
the surrounding environment. 
4.1.2 Secondary Conceptual Designs 
 Taking the aforementioned minimal cell loss requirement into consideration, a secondary 
group of conceptual designs were developed as shown in Figure 14. The general ideas of the 
designs remain the same as the primary designs, with the exception of the scaffold extending 
further to allow for less cell exposure. This would allow for minimal cell loss and migration as 
there are fewer cells exposed in the atrium and the ventricle, therefore decreasing the amount of 
cells that may migrate away from the bridge. However, the threads and some cells still protruded 
from the scaffold, leaving room for improvement upon the designs. 
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Figure 14: Second conceptual designs: bundle (left), funnel (center) and socket (right). 
 
4.1.3 Final Conceptual Designs 
 The final conceptual design was developed in order to completely encapsulate the fibrin 
microthreads and hMSCs within the scaffold. The only exposure of the cells to the environment 
would be through the gap junctions between the hMSCs and native cardiomyocytes through the 
porous encapsulating scaffold in order to collect and deliver the current. The team believed this 
to be the ideal conceptual design with which to move forward in the development of preliminary 
designs of the AV nodal bridge. The design could be applied to the plain bundle, funnel and 
socket designs described above. Figure 15 below displays this design in the funnel styled option. 
 
 
Figure 15: Final conceptual design in the form of the funnel scaffold. 
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4.2 Preliminary Designs  
 Following further discussion between the team and the client, preliminary designs were 
developed to account for cell loss accompanying the conceptual designs. The client brought to 
the team’s attention the function of containing the current throughout the bridge. In the 
conceptual designs, this function was not properly considered. The preliminary designs reflect 
the consideration of this function, as the designs only allow for gap junction formation in the 
portions of the bridge that will be utilized collect and deliver current. The center portion of the 
bridge will inhibit gap junction formation in order contain the current and cells, while allowing 
for nutrients to diffuse into the bridge to maintain cell viability.  
 The preliminary designs show two sections of the bridge distinguished by different pore 
sizes and thicknesses within the scaffold. Larger pores were located on the ends of the scaffolds 
to allow for the gap junction formation between the seeded hMSCs and native cardiomyocytes. 
The remaining, center portion of the scaffold had smaller pore sizes to inhibit this gap junction 
formation. The developed preliminary designs are displayed and discussed below in reference to 
the key shown in Figure 16. 
 
 
Figure 16: Key for the preliminary design images shown below. 
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 An additional method of minimizing cell loss was considered in the preliminary designs. 
Each of the preliminary designs described have all ends of the scaffold sealed. It is believed that 
by sealing the ends of the scaffolds, the cells will have a decreased risk of migrating from the 
threads or scaffold. The method of sealing will be discussed further in a later section.  
 Overall, the two groups of preliminary designs described below present feasible design 
options for the development of a final design. 
4.2.1 ‘Flattened Straw’ Designs 
 After presenting the conceptual designs to the client and discussing more within the team, 
the possible concern of excess space within the scaffold was raised. Excess space may create 
microenvironments that can promote bacterial growth within the scaffold. This was undesirable 
for the AV nodal bridge, as bacteria may cause an unwanted immune response within the body. 
Therefore, two preliminary designs were developed to be flat, as shown in Figure 17 below.  
 
Figure 17: 'Flattened Straw' plain bundle (left) and ‘Flattened Straw’ funnel (right) preliminary designs. 
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 The primary concern with this design was implantation within the heart. With the team 
focusing on a minimally invasive catheter delivery of the device, it was important to consider 
that these preliminary designs would be unable to be delivered via catheter, as they are not in 
cylindrical form. 
 The funneled ends of the preliminary design shown above also presented a constraint in 
catheter delivery, as the cylindrical catheter would be unable to account for a wider diameter of 
the funneled ends. If the design were to be altered to allow for the funneled ends to meet the 
maximum diameter the catheter can withhold, this would limit the amount of space for fibrin 
microthreads and cell seeding. Having the appropriate amount of hMSCs to allow for the 
propagation of current was a more important objective than the delivery of the bridge as seen in 
the Pairwise Comparison Chart. Therefore, the diameter alterations that accompany the funneled 
design would not be acceptable. 
 The method of fabrication of the funneled ends is also a major concern of the funneled 
end preliminary design shown in Figure 17. The methods of scaffold fabrication under 
consideration will be discussed in a later section. However, each method of fabrication will 
present a challenge in developing a funneled-like scaffold. 
4.2.2 Cylindrical Designs 
 Considering catheter implantation of the final design, two preliminary designs were 
developed to be in cylindrical form as shown below in Figure 18. These two designs were similar 
to the aforementioned flattened straw designs, however they were in cylindrical form in order to 
account for the delivery mechanism. 
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Figure 18: Cylinder plain bundle (left) and cylinder funnel preliminary designs. 
 
After analyzing both groups of preliminary designs with the team and client, primary 
concerns of bacterial growth in microenvironments and the use of funneled ends were brought to 
the attention of the team. Within the cylindrical scaffold, there was likely to be hollow space 
between the seeded microthreads and the encapsulating scaffold. This would increase the 
presence of bacterial microenvironments. Also, as previously mentioned, the funneled ends cause 
complications in fabrication and catheter delivery. 
4.3 Scaffold Material Analysis 
The encapsulating scaffold material incorporated into the AV node bypass mechanism 
must be composed of a non-degradable material.  After the implantation and eventual 
degradation of the seeded fibrin microthreads, the cells composing the bypass mechanism must 
remain encapsulated by the outer scaffold. If the necessary amount of viable cells is not sustained 
locally within the heart, the device would not be able to propagate an electrical signal and would 
not complete its crucial function. The porous scaffold must not allow cells to migrate out of the 
device and wander into other areas of the heart. Not only would the AV node bypass mechanism 
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be dysfunctional, but also the migrating hMSCs could cause potentially harmful effects 
throughout the heart. 
Prior to scaffold fabrication, the team conducted a thorough investigation of a range of 
materials. The scaffold material utilized must be biocompatible and minimize cells loss. The 
ideal scaffold material must be able to insulate the electrical current as it is passed from the SA 
node, through the device, bundle of His, and into the ventricles while minimizing the loss of 
current. To encapsulate the cells, the scaffold material must be non-degradable, insulatory, 
porous, flexible, and bioinert. The mechanical properties of the material were important to 
consider, as the scaffold must possess a high degree of elasticity, a high toughness and durability, 
and a low stiffness to withstand the contractile forces and cyclic loading of the heart. Based on 
these criteria, three materials were researched in depth for the application of an encapsulating 
scaffold: polyurethane (PU), polyethylene terephthalate (PET), and polytetrafluoroethylene 
(PTFE). Table 4 displays a summary of material properties of these three materials analyzed in a 
previous Major Qualifying Project completed at Worcester Polytechnic Institute in 2009. In 
addition, a proprietary material, ‘Poly-X’, had the potential to act as an insulator scaffold. 
4.3.1 Polyurethane 
Polyurethane is a thermoplastic, which is commonly utilized for its excellent mechanical 
properties and biocompatibility [59]. This material is known to demonstrate high toughness and 
durability similar to that of metal, while still possessing a high degree of elasticity [60]. Non-
aromatic polyurethanes are known to have stronger adhesive properties and increased flexibility 
compared to aromatic polyurethanes [61]. Research has shown that polyurethane performs best 
under uniaxial tensile loading [61]. Polyurethane has a segmented block co-polymeric structure 
composed of diisocyanate, a chain extender and macrodiol (or polyol) [59]. Reaction of the three 
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primary materials results in the formation of linear segmented copolymers. The physicochemical 
properties of polyurethane can be modified by altering the ratio of hard segments to soft 
segments contained within copolymers [59]. The physical properties, as well as the blood and 
tissue compatibility can also be easily altered [59]. While polyurethane is classified as a non-
degradable material, it is susceptible to oxidative, enzymatic, and hydrolytic degradation in vivo 
[59]. Non-thermal degradation of some polyurethane products may begin as low as 150 ºC 
(300ºF) to 180ºC [62]. A variety of chemical modifications, such as crosslinking the materials 
with multi-functionalized natural compounds, can improve the biodegradability and 
biocompatibility of the material [60]. Chemically altered polyurethane can exhibit a degradation 
range between weeks and years [59]. Some of the biomedical applications of polyurethane 
include pacemaker leads, catheters, prosthetic valve leaflets, and coating materials for breast 
implants [59]. 
4.3.2 Polyethylene Terephthalate 
Polyethylene Terephthalate (PET) is an essential technical plastic utilized as an 
engineering material within small, high-performance parts [63], [64]. While most often found as 
a semi-crystalline polymer, PET can undergo heat treatment during production to alter its 
percentage of crystallinity [64]. PET exhibits a low corrosion resistance and the widest 
temperature range of any polymer [64]. A unique property of PET is that its coefficient of 
friction is among the lowest of all materials [64]. Wear reducing compounds can also be sintered 
with PET to decrease the coefficient of sliding friction even further [64]. PET also exhibits the 
highest resistivity amongst a wide range of materials, possessing a very high dielectric strength 
and low dielectric loss. The material properties of PET make it a common material for 
applications such as plastic containers to hold food, beverages, cosmetics products, and 
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pharmaceutical products [63]. 
4.3.2     Polytetrafluoroethylene 
Polytetrafluoroethylene, also known as Teflon, is a porous monofilament plastic polymer 
[65]. PTFE exhibits a high degree of flexibility and durability, as well as a high breaking strength 
[65]. While being negatively charged and permeable to many biomolecules and gases, 
polytetrafluoroethylene has the ability to simulate the thin layer of cells lining the inner surface 
of blood vessels, known as the endothelium [65]. This specific ability makes PTFE ideal in 
applications such as synthetic conduit materials for vascular bypass to treat heart disease and 
replacement of pericardium after cardiac surgical procedures [65]. 
4.3.3 ‘Poly-X’ 
Currently ‘Poly-X’ is being utilized in hollow fiber tubules at the University of Bath, 
England. Mechanical properties of ‘Poly-X’ remain unknown to the team. However, after 
meeting with the researcher from the University of Bath, the team was informed of the material’s 
potential in the application of an AV nodal bypass mechanism. ‘Poly-X’ is a non-cell adhesive 
polymer that is biocompatible when implanted in vivo. Thus, ‘Poly-X’ remains a viable option as 
an insulator scaffold. 
 Moving forward, a PU/PET blend utilized for its combined properties and ‘Poly-X’ were 
assessed for design feasibility. 
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Table 4: “Summary of Candidate Material Properties” [66] 
 PET ePTFE PU (ChronoFlex® C) 
Biocompatible Yes Yes Yes 
Cytotoxic No No No 
Elastic Modulus 40-60*104 psi 5.8-8.01*104 psi 0.775-1.9*104 psi 
UTS 7.01-10.5 ksi 2.9-4.35 ksi 5.5-7.5 ksi 
Yield Strength 
(Elastic Limit) 
8.19-9.04 ksi 2.18-3.63 ksi N/A 
Multiaxial Fatigue 2.8-4.2 ksi (at 107 
cycles) 
0.834-1.02 ksi (at 
107 cycles) 
N/A 
Shear Modulus 0.144-0.216*106 psi 0.02-0.0276*106 
psi 
N/A 
 
4.4 Feasibility Analysis 
The feasibility of each design aspect of the AV nodal bridge must be assessed prior to the 
development of a final prototype. The feasibility study was used to analyze the conceptual and 
preliminary designs in order to develop final design alternatives. Various tests on cell viability 
and cell migration were then performed on the final designs to determine the optimal design for 
the final prototype of the AV bridge.  
4.4.1     Delivery Feasibility  
The team decided to use a method of catheter implantation as a minimally invasive 
method to insert the device into the heart. The specific catheter the team planned to use was the 
catheter discussed in Chapter 2 developed by a 2011 Major Qualifying Project team. The method 
of device implantation using this catheter presented a number of constraints to consider in the 
development of the AV node bypass mechanism.  
Protection of the scaffold, thread, and cellular components of the device must be ensured 
to result in effective device implantation and function. Without safe and secure insertion through 
a catheter device, the necessary amount of viable cells would not be delivered into the heart and 
the signal would not be propagated into the right ventricle, compromising the function of the 
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device. The method of implantation influenced the size, shape and material composition of the 
device to guarantee that the device could fit in the catheter. Specifically, the current design of the 
catheter only accommodates for materials of maximum 1.0 mm in diameter. The team needed to 
consider the flexibility of the material and the forces experienced by the device, specifically if it 
would be in tension or compression during implantation throughout catheter insertion. If the AV 
node bypass mechanism is not designed with the proper mechanical properties, the device could 
experience mechanical failure before complete implantation.  
Through discussion with one of the students of the catheter Major Qualifying Project 
team, it was confirmed that these constraints could be overcome for the bridge design. The 
student believes the catheter design could be slightly altered to accommodate for the AV nodal 
bypass bridge. This confirms the feasibility of the use of catheter implantation for the final 
design. 
4.4.2     Structure 
The first design aspect that was evaluated for feasibility was the structure of the AV 
bridge, specifically the insulating scaffold. After further discussion with the client, it was decided 
that the cylinder formation of the preliminary designs was ideal due to its ease of catheter 
implantation. The cylindrical scaffold would be flattened when implanted into the heart due to 
the contractile and cyclic forces it will experience as stated by the client. The flattening of the 
cylindrical scaffold will decrease the likelihood of bacterial growing in microenvironments 
within the device.  
After deciding upon a cylindrical scaffold, the plain bundle and funnel cylindrical 
scaffolds were assessed for feasibility. The funnel scaffold presents limitations to the fabrication 
methods utilized, such as electrospinning. Different fabrication techniques would be needed to 
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create the straight cylindrical shape and the funneled ends. In addition, the diameter of the 
funneled ends would significantly impact the catheter delivery method, and thus the diameter of 
the straight section. The outer diameter of the funneled ends must not be greater than 1mm, the 
inner diameter of the specialized catheter. Therefore, the outer diameter of the straight section 
must be decreased. This may present further limitations loading the scaffold with threads seeded 
with hMSCs. Due to these limitations, the final design will be based upon the plain, cylindrical 
bundle. 
4.4.3     Fabrication Methods 
After assessing structure of the scaffold, the feasibility of various fabrication methods 
were assessed. Fabrication methods under consideration were laser micro-etching, 
electrospinning, and solvent casting and particulate leaching. 
4.4.3.1     Laser Micro-etching 
Upon initial analysis, working with a collaborative team in Lithuania to produce a laser 
micro-etched scaffold seemed feasible. The laser micro-etching fabrication method allows for 
consistently produced and controlled pore sizes. Pore control would allow for large pore sizes on 
the ends of the scaffold to promote gap junction formation and smaller pore sizes along the 
center of the scaffold to allow for nutrient passage as well as prevent cell migration. This method 
would allow for variations in pore sizes to be feasible without altering the thickness throughout 
the scaffold. However, with time as a major project constraint, it was determined that it was not 
feasible to ensure that the scaffold is fabricated and shipped with enough time to perform cell 
viability tests and collect data for the final project presentation in April 2015. 
4.4.3.2     Electrospinning 
 The second fabrication method assessed for feasibility was electrospinning. 
Electrospinning is a common fabrication method used to produce porous scaffolds. A previous 
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Major Qualifying Project completed at Worcester Polytechnic Institute in 2012, successfully 
produced an electrospun scaffold made of a PU/PET blend [67]. However, one limitation of 
electrospinning is limited pore size control and consistency. Thus, it is difficult to produce the 
desired pore sizes uniformly along the entirety of the scaffold. After speaking with BioSurfaces 
Inc., an electrospinning company based out of Auburn, MA, a method of attempting to control 
this pore size was developed. The company provided the knowledge of the correlation between 
the thickness of the scaffold and the pore sizes produced through electrospinning. The thicker the 
scaffold, the smaller the pore sizes, and vice versa. There is no direct way to control the pore 
sizes produced through electrospinning, however, the thickness of the scaffold can be controlled.   
 BioSurfaces developed a method of producing an electrospun cylindrical scaffold to our 
specifications. After spinning a cylindrical mandrel to attempt to produce the thickness for 2.0- 
2.5 µm pore sizes that were necessary for gap junction formation, the center of the mandrel could 
be spun again to produce smaller pore sizes. However, this impacted the thickness of the center 
of the tube and may have decreased the area in which the threads must be inserted, in addition to 
restricting catheter loading. The team decided the feasibility of this fabrication method should be 
further assessed through experimentation, as discussed in a later section. 
4.4.3.3     Solvent Casting and Particulate Leaching 
To assess the final fabrication method of solvent casting and particulate leaching, the 
team met and spoke with a researcher from the University of Bath in regards to the development 
of ‘Poly X’ hollow fiber tubules through this fabrication method. The team planned to further 
assess this material and pore size feasibility in regards to this method during a future 
correspondence with the University of Bath.  
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4.4.3.3.1     Material Analysis 
Upon previous material analysis, it was determined that the scaffold would be composed 
of PU/PET utilized for its combined properties. However, after speaking with the researcher of 
the University of Bath, the team was informed that hollow fiber tubules have not been produced 
with a PU/PET blend in the past. Currently, the tubules are composed of a proprietary polymer, 
‘Poly-X’ which is non-degradable and non-cell adhesive. The team decided to look into possible 
solvents that could be utilized in order to create a PU/PET hollow fiber tubule. For this to be 
possible, one solvent must dissolve PU and PET while the other solvent must not. In addition, 
both solvents must be miscible for a successful tubule to be fabricated. 
 Throughout discussion, it was determined that ‘Poly-X’ was a potential material that 
could be utilized in the AV bridge. Specifically, a scaffold consisting of ‘Poly-X’ in the center 
would prevent hMSCs from adhering to the scaffold and potentially forming gap junctions 
through the pores. Thus, the cell-adhesive PU/PET blend could be sealed onto the ends of the 
‘Poly-X’ scaffold to promote gap junction formation. In the event that producing a PU/PET 
hollow fiber tubule was not plausible, electrospinning PU/PET ends of the scaffold remained a 
feasible option despite uncontrollable pore sizes. These ideas are presented in the following 
section, Decisions on Final Designs. The feasibility of a complete PU/PET hollow fiber tubule 
and a ‘Poly-X’/PU/PET tubule needed to be further assessed through analysis. 
4.4.3.3.2     Pore Size Analysis 
The feasibility of controlled pore size is another design aspect that was evaluated. Solvent 
casting and particulate leaching offers more control over pore size compared to electrospinning. 
The preliminary scaffold designs consist of two different pore sizes, < 0.4µm in the center to 
promote the nutrient diffusion and inhibit cell migration and 2-2.5µm on the ends to promote gap 
junction formation between hMSCs and native cardiomyocytes. After speaking with the 
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University of Bath, the researcher informed the team that the smallest pore size produced 
through the method of solvent casting and particulate leaching was 2.0 µm. Upon further 
analysis, a tube of consistent pore size (2.0 µm) and thicker inner diameter of the center of the 
scaffold may still be able to prevent cell migration and prevent gap junction formation along the 
middle of the tube. Utilizing ‘Poly-X’ as a non-cell adhesive material in the center of the tubule 
also remained a feasible option. However, the feasibility of sealing thinner PU/PET ends to the 
center of the scaffold must be addressed. Further analysis of using a uniform pore size, varying 
scaffold thickness, and utilizing ‘Poly-X’ needed to be completed.  
4.4.4     Sealing Methods 
Sealing ends of different pore size or material to the center of the scaffold is vital for gap 
junction formation, while prohibiting the migration of the cells out of the ends of the scaffold. 
However, sealing methods must not affect cell viability or structural integrity of the scaffold. 
Two sealing methods were investigated: heat sealing and BioGlue®. 
4.4.4.1     Heat Sealing 
Heat sealing is a sealing method that has been utilized in previous Major Qualifying 
Projects at WPI. However, the use of heat to seal a small diameter scaffold required complete 
control and precision. Sealing the ends of the scaffold would occur once the threads seeded with 
hMSCs are inserted into the scaffold. Using heat to seal the ends prevents a harmful risk to the 
viability of cells and structural integrity of the scaffold. Due to the importance of cell viability, 
heat sealing too close to the microthreads was deemed a risk. However, this method was still 
tested on the scaffolds, as discussed in a later section. 
4.4.4.2     BioGlue® 
In order to seal the ends of the scaffold, the use of BioGlue® was considered as an 
option. BioGlue® reduces the risk of scaffold denaturation due to heat and potentially presents a 
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lesser risk of cell death in comparison to heat sealing. Micro-forceps can be used to secure the 
scaffold and apply to BioGlue® to a controlled area. The overall feasibility of using BioGlue® 
to seal a small diameter tubule needed to be assessed further through experimentation. However, 
due to time constraints and availability of the product, the team was unable to obtain the product 
to perform testing with. Therefore, heat sealing was the primary method of sealing analyzed as 
discussed in later sections.  
4.4.5     HCN Transfected Cell Availability 
In terms of the functional AV nodal bypass mechanism, assessment of the function of the 
bridge to pass current along the length of the bridge with minimum current drop between the 
atrium and the ventricle was inhibited. The availability of HCN transfected hMSCs was a large 
factor, as these cells are needed along the length of the bridge to fire action potentials in the case 
of current loss in the radial direction. Professor Gaudette stated that the ability to obtain these 
cells for this project was highly unlikely. Also, the cost of HCN transfected cells may have 
exceeded our budget constraint. As an alternative, non-transfected hMSCs in addition to neonatal 
rat cardiomyocytes were utilized. Therefore, it was not feasible to test the full functionality of the 
final prototype within the budget and time constraints. 
4.5 Decisions on Designs 
 Taking the preliminary designs and the concerns with each into consideration with the 
various methods of fabrication, the team narrowed potential designs down to three viable 
options. The designs make use of the hollow fibers from the University of Bath in England and 
electrospinning methods of fabrication, as mentioned above in the feasibility study. 
4.5.1 Option 1: ‘Poly-X’ and PU/PET Hollow Tubes 
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The first option developed by the team was a scaffold with the center portion consisting 
of a ‘Poly-X’ hollow tube and two ends made of PU/PET hollow tubes as shown in Figure 19. 
The two portions of the scaffold would be fabricated separately and glued or heat sealed 
together. The entire scaffold would ideally have pore sizes of approximately 2-2.5 µm. This pore 
size on the ends of the scaffold would allow for the gap junction formation between the native 
cardiomyocytes and the hMSCs within the encapsulating scaffold. The center ‘Poly-X’ portion 
would have this pore size, but be thicker than the ends to prevent gap junction formation, as it 
was necessary to minimize current loss throughout the bridge. The ends of this scaffold would be 
sealed to prevent cell loss, as discussed above in the preliminary design section. 
 
 
Figure 19: Design Option 1: Red is the PU/PET Hollow Tubes; Grey is the Poly-X Hollow Tube Scaffold. 
 
The major limitation in regards to this design was the availability of a solvent and non-
solvent that correlates with the PU/PET substance to allow for the fabrication of the hollow 
tubes. If this information could not be obtained, or is nonexistent, this design would not be 
viable. 
4.5.2 Option 2: ‘Poly-X’ Hollow Tube and PU/PET Electrospinning 
The second option for the design the team developed is shown below in Figure 20. The 
center portion would be made of a ‘Poly-X’ hollow tube, while the ends would be made of a 
PU/PET electrospun material. These two portions would be sealed together to create the entire 
scaffold. Again, the pore size of the entire scaffold would be approximately between 2-2.5 µm 
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with the center portion having a greater wall thickness to prevent gap junction formation. Again, 
the ends would be sealed to prevent cell migration from the scaffold. 
 
 
Figure 20: Design Option 2: Blue is the PU/PET Electropun Scaffolds; Grey is the 'Poly-X' Hollow Tube Scaffold. 
 
4.5.3 Option 3: PU/PET Electrospinning 
The third and final option developed by the team is a complete PU/PET electrospun 
scaffold as shown in Figure 21. This would be an option if the hollow tubes were deemed 
unfeasible or unavailable. The center portion of the PU/PET scaffold would ideally have smaller 
pore sizes of about < 0.4 µm to allow for the nutrients to enter the device, but prevent the cells 
from migrating or forming gap junctions. This portion would naturally be thicker due to the pore 
size of electrospun materials being proportional to the thickness of the material. The ends of this 
scaffold design would ideally have pores of size 2-2.5 µm to allow for the gap junction 
formation. Again, the ends of the scaffold should be sealed to prevent migration of the hMSCs. 
 
 
Figure 21: Design Option 3: Blue is the PU/PET Electrospun Scaffold 
 
4.5.4 Design Specifications 
 A number of specifications were confirmed for the design as shown below in Table 5.  
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Table 5: Ideal Design Specifications 
Scaffold Pore Size of 
Hollow 
Tubes =  
2-2.5 µm 
Pore Sizes of 
Electrospun 
Scaffolds =  
2-2.5 µm 
and 
 < 0.4 µm 
Wall 
Thickness 
for Gap 
Junction 
Formation = 
10-20 µm 
[68] 
Wall 
Thickness 
for Hollow 
Tubes = 
> 90 µm 
[68]  
Length of 
Ends of 
Scaffolds = 
0.4 cm 
Fibrin 
Microthreads 
Bundle  
Size = 
6 or 12 
threads 
    
hMSCs 100,000 
seeded 
    
Entire Design Length = 
> 2 cm 
Outer 
Diameter =  
1 mm [57] 
   
 
 As mentioned above in the feasibility study, the pore size of the hollow tubes could not 
be made as small as the desired < 0.4 µm. However, the pore size could still remain at a size of 
2-2.5 µm if the thickness of the center of the device was increased. The wall thickness of the 
ends of the scaffold where gap junctions form should be 10-20 µm, as calculated in previous 
MQP work to be ideal for gap junction formation [68]. The thickness of the ‘Poly-X’ center 
portion tubes would be > 90µm [68] as this number has been shown to prevent migration of 
hMSCs. The length of the caps, or ends, of the scaffolds would be about 0.4 cm on each end of 
the scaffold if it were to be 2 cm long, allowing for the center portion of the scaffold to be a 
minimum of 1.2 cm in length. The client suggested to begin testing with a 6 or 12 thread bundle 
of fibrin microthreads and seeded with 100,000 hMSCs. In studies conducted in the client’s lab 
at WPI, the 12 thread bundle had been shown not to inhibit cardiomyocyte contraction and 
promote passage of current. Overall, the entirety of the design would have a minimum length of 
2 cm and an outer diameter of 1-2 mm [57]. 
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4.5.5 Design Calculations 
4.5.5.1 Surface Area of Cylindrical Bridge 
 
   
 
 
4.5.5.2 Forces Exerted by the Heart 
 The human heart exerts average blood pressures of 120 mmHg in systole (contraction) 
and 80 mmHg diastole (relaxation). These pressures can be converted into forces exerted by the 
heart, which will therefore also be exerted on the AV bridge. The equations below determine the 
mechanical strength the scaffold will need to withstand in the case of the length of the bridge 
being the minimum of 2 cm with a diameter of 1 mm. 
  
 
 
 
 
 
2 cm 
 
1-2 mm 
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4.6      Feasibility Testing 
 In testing the feasibility of the design, the team moved forward with the electrospinning 
fabrication method as the availability of the hollow tubules was deemed unfeasible. Various 
samples of electrospun PU/PET scaffold were obtained at 20, 40, and 50 Pm. The feasibility of 
the design was evaluated based on scaffold thickness in relation to pore size. 
  
4.6.1 Sealing and Thread Insertion Methods 
 In terms of the methods of sealing the ends of the encapsulating scaffold, heat sealing and 
needed to be tested accordingly in order to confirm the use of the method of sealing for use in the 
AV bridge. Experiments were performed in non-sterile environments with the PU/PET scaffolds 
of any size thickness.  
For heat sealing, the scaffold material was tested using a soldering tip, hereon described 
as a fine-tip heat source. The fine-tip heat source was controlled in terms of temperature to 
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assure the heat applied would shrink the material, while not degrading the material. The fine-tip 
heat source was applied to the scaffold and also held at a distance from the scaffold so 500-
600qF, as both heat sources were likely to melt the scaffold. The resulting sealed scaffold 
samples were observed and imaged using microscopy in order to visually confirm that the 
method sealed the scaffold.  
During the first set of experiments, the scaffolds were tested without any cells seeded on 
the materials. This ensured that the heat sealing was working properly before involving the use 
of cells, and that the heat does not cause excessive damage to the scaffold. After the heat sealing 
was deemed possible and did not harm the material too much, the overall AV nodal bypass 
device was assembled. 45,000 hMSCs seeded on a 6X suture of fibrin microthreads were 
encapsulated in a cylindrical scaffold sample. The ends of the scaffold with the seeded threads 
inside were then sealed using the fine-tip heat source. This test allowed the determination of the 
cell viability after heat sealing. 
Finally, after heat sealing was confirmed as a viable method of sealing, decisions on 
where the scaffold would be sealed were concluded. The team brainstormed three possible 
methods of how the seeded fibrin microthreads can be inserted into the encapsulating scaffold, 
which all involve the need for sealing in different places of the scaffold. Figure 22 through 
Figure 24 show the options that were considered in order to determine the optimal method of 
inserting threads into the encapsulating scaffold. 
 
 
Figure 22: Thread Insertion Option 1 
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Figure 23: Thread Insertion Option 2 
 
 
 
 
Figure 24: Thread Insertion Option 3 
 
Figure 22 shows the seeded threads simply being pulled through the cylindrical scaffold 
with a straight needle. In this option, the ends of the cylindrical scaffolds would be the only area 
that needed to be sealed. Figure 23 shows the scaffold being cut in the center across the yellow 
dotted lines where the seeded threads can be inserted into the scaffold one end at a time. In this 
option, the scaffold would need to be sealed at the cut center, as well as at the ends of the 
cylindrical scaffold. Figure 24 shows the tubular scaffold being cut across its length to allow the 
tube to be opened for insertion of the seeded threads. This option called for the cut length across 
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the scaffold to be sealed, as well as the ends of the tube. Through discussion the team determined 
that option was the most feasible in terms of minimizing sealed surface area and maintaining cell 
viability.  
4.6.2 Cell Viability 
 It is important that the scaffold material used did not harm the cells. To determine if the 
PU/PET scaffold was biocompatible, LIVE/DEAD staining was performed. According to the 
procedure in Appendix III, this test utilizes Hoechst dye, ethidium homodimer , and calcein AM 
to determine the cell viability of the samples. Hoechst dye is a florescent dye that stains the DNA 
of live and fixed cells. Ethidium homodimer is a fluorescent dye that is unable to pass through 
the membrane of living cells. When cells are dead, the membrane is disrupted allowing for the 
ethidium homodimer to enter the cell and stain the DNA in the nucleus. Calcein AM is a 
fluorescent dye that has the ability to pass through the cell membrane of a living cell. This dye 
enters the living cell and fluoresces the cell cytoplasm. Therefore, living cells are stained with 
one fluorescent dye, dead cells are stained with a separate fluorescent dye, and all nuclei are 
fluoresced during the same procedure. In terms of the AV bridge, LIVE/DEAD staining was 
primarily performed on PU/PET scaffold samples of 20, 40, and 50µm thick seeded with 
approximately 40,000 hMSCs in order to determine the toxicity of this material in terms of cell 
viability. 
4.6.3 Migration  
 In order to determine if the encapsulating scaffold successfully prohibits the migration of 
cells from the AV bridge, Hoechst and Phalloidin staining was performed. As stated above, 
Hoechst is a fluorescent stain that binds to the nuclei of cells, while Phalloidin is a chemical that 
binds to the F-Actin in the cells. According to the procedure found in Appendix IV, 
approximately 80,000 hMSCs were seeded on one side of the scaffold using the Gaudette-Pins 
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transwell as shown in Figure 25 and incubated for 4 days. Following the incubation period, the 
cells were fixed and stained with Hoechst and Phalloidin to visualize the location of the cells. 
Both sides of the scaffold were imaged using fluorescent microscopy in order to determine if any 
cells migrated through the pores. This test was performed on scaffolds with thicknesses of 20μm, 
40μm and 50μm in order to determine the optimal thickness to prevent migration.  
 
Figure 25: Gaudette-Pins Well 
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Chapter 5: Design Verification Results 
5.1 LIVE/DEAD Staining 
 Initially, it was vital to ensure the PU/PET scaffold material was biocompatible and did 
not harm the cells. A number of samples of the scaffold at thickness of 20 µm, 40 µm and 50 µm 
were seeded with hMSCs and were incubated for four days. Following this incubation period, the 
scaffolds with hMSCs were stained with blue Hoechst, green calcein AM, and red ethidium 
homodimer dyes and then imaged through the use of fluorescent microscopy. Images obtained at 
10x are shown in Figures 26 and 27 below and were utilized for calculations of the cell viability.  
    
Figure 26: Samples 1 & 2: 20µm scaffolds with a 96.3% cell viability (left) and a 98.2% cell viability (right) with the scale bar 
representing 150 µm 
    
Figure 27: Samples 3 & 4: 40µm scaffolds with a 97.2% cell viability (left) and a 98.6% viability (right) with the scale bar 
representing 100 µm 
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ImageJ software was used to count the total number of nuclei, the number of living cells, 
and the number of dead cells, as shown in Table 6 below for the samples shown in the figures 
above. A ratio of living cells to total cells was calculated and an average of 97.8 + 1.03% cell 
viability was determined. 
Table 6: Results of LIVE/DEAD staining on four scaffold samples 
     Nucleus Count    Dead Cell Count Viable Cells 
Sample 1 (20 µm) 2167 38 98.2% Sample 2 (20 µm) 2005 75 96.3% Sample 3 (40 µm) 992 14 98.6% Sample 4 (40 µm) 775 21 97.2%  
5.3 Cell Migration 
 Cell migration testing was performed to determine the ideal thickness of the scaffold to 
prevent cells from wandering outside of the device. Cells were seeded onto one side of 20 µm, 
40 µm, and 50 µm scaffolds and allowed to incubate for four days. Following the incubation 
period, the cells were stained with Hoechst and Phalloidin dyes in order to visualize the cells 
through fluorescent microscopy, shown Figures 28-30 below.  It was determined that the 20 µm 
thickness was too thin and allowed for cell migration through the scaffold material, whereas the 
40 µm and 50 µm samples prevented cell migration as the images in Figures 29 and 30 only 
shown the auto fluorescence of the scaffolds in the images obtained of the bottom of the 
scaffolds. 
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Figure 28: Hoechst and Phalloidin on top (left) and bottom (right) of 20µm scaffold with the scale bar representing 100 µm 
    
Figure 29: Hoechst and Phalloidin staining of top (left) and bottom (right) of the 40 µm scaffold with the scale bar representing 
100 µm 
    
Figure 30: Hoechst and Phalloidin staining on top (left) and bottom (right) of the 50 µm scaffold with the scale bars representing 
100 µm 
 
5.3 Heat Sealing 
As previously mentioned, the ends of the scaffold were clamped together using forceps 
and a fine tip heat source was applied to each end. The PU/PET scaffold was then imaged using 
high magnification microscopy as shown in Figure 31 below.  
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To ensure the heat sealing did not negatively harm the cells, LIVE/DEAD staining was 
then performed on the sealed scaffold. 45,000 hMSCs were seeded onto fibrin microthreads and 
were stained utilizing blue Hoechst dye, red ethidium homodimer, and green calcein AM 
following the extraction of the thread from the sealed scaffold after the fine-tip heat source was 
applied. The cells were then imaged utilizing fluorescent microscopy as see in Figure 32 below. 
 
Figure 32: LIVE/DEAD staining of hMSCs on fibrin microthreads immediately after heat sealing 50 µm  PU/PET scaffold 
Figure 31: Seal of scaffold sample displayed in the center of 
the PU/PET scaffold 
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The blue circles in the above image represent cell nuclei. Living cells can be seen where 
there is green surrounding the blue nuclei, whereas dead cells can be seen where there is red 
concentrated inside of the blue nuclei. 
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Chapter 6: Discussion 
 
This project began the initial development of an AV nodal bypass device through the 
production of an encapsulating PU/PET electrospun scaffold. The project’s focus on the 
encapsulating scaffold allowed for the addressing of a number of the main functions desired for 
the final AV bridge device. The collecting, passing and delivering of current from the atrium to 
the ventricle with minimal loss of the current along the length of the bridge, as well as the 
minimal loss of the cells within the device, were both accounted for through the development of 
the encapsulating scaffold. 
6.1 LIVE/DEAD Staining Results 
Biocompatibility of the overall device is ranked as the third most important objective 
according to both the team and the client as discussed in Section 3.2. The device must not be 
cytotoxic to the patient or the hMSCs used within the device. In order to test for the 
biocompatibility of the scaffold, the team performed LIVE/DEAD staining on hMSCs seeded 
onto the scaffold samples in order to determine if the scaffold would be cytotoxic to this specific 
cell type. The results shown in Section 5.1 verify the biocompatibility of the PU/PET material for 
its use as the encapsulating scaffold for the AV node bypass device.  
A sample of four scaffolds seeded with hMSCs that underwent the LIVE/DEAD staining 
were analyzed with ImageJ software in order to determine the ratio of viable cells to dead cells 
found on the scaffold. Cell nuclei stained with Hoechst dye were counted on the representative 
images with the ImageJ software, while the dead cells within the images were counted manually. 
Cells were characterized as dead when the red ethidium homodimer dye aligned with the blue 
Hoechst dye within the nucleus of a cell. Through this method of counting, it was determined 
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that the average cell viability on the scaffold samples was approximately 97.8 + 1.03% by taking 
the average viability percentages of each of the four samples shown in Table 6. These 
calculations numerically verify the biocompatibility of the scaffolds. 
6.2 Migration Study Results 
As mentioned above, the migration of cells is an undesirable characteristic of the AV 
node bypass device. The loss of cells via migration through the scaffold pores needed to be 
controlled for the device to function as desired. Therefore, migration testing was performed on 
the three different thicknesses of the scaffold: 20 μm, 40 μm and 50 μm. The results of these tests 
presented in Section 5.2 show that the 40μm and 50μm samples were preferable for the use in the 
device, as they successfully prevented the migration of the hMSCs from the top of the scaffold to 
the bottom of the scaffold over an incubation period of 4 days. However, as shown in Figure 28, 
the 20 μm scaffold sample was unable to prevent the migration of the cells as a large number of 
hMSCs were seen on the bottom of the scaffold after the 4 day incubation period. Therefore, 
these results allowed for the team to conclude that the use of the 20 μm scaffold thickness is 
unwarranted for the AV node bypass device. These results also support the recommendation of 
the use of a PU/PET scaffold for the final device that has a thickness in all sections of the device 
greater than or equal to 40-50 μm, as migration of cells needs to be contained throughout the 
entire device. 
6.3 Heat Sealing Results 
Based on the desired functions of the device, cell loss and migration would be 
detrimental to the overall function of the AV node bypass device. With the loss or migration of 
cells from inside the encapsulating scaffold to the external environment of the heart, there may 
be an inability for gap junctions to form between all hMSCs along the length of the bridge, in 
turn inhibiting the passage of current from the atrium to the ventricle. Without enough cells in 
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the device, the main function of collecting, passing and delivering the current from the atrium to 
the ventricle would not be able to be completed.  
In order to prevent the loss of cells and migration of cells from the two ends of the final 
device, heat sealing testing was performed on cylindrical scaffold samples as described in 
Section 5.3 Observations made under an inverted microscope visually confirm that the scaffold 
samples were successfully sealed with the application of a fine tip heat source. There was no 
light that was able to shine through the scaffold samples at the sealed area, suggesting that the 
seal was complete. In addition, the results of the LIVE/DEAD staining of the sealed hMSC 
seeded fibrin microthreads located inside of the scaffold sealed with the fine tip heat source 
suggest that the heat source did not negatively affect the cells. These results verify the use of a 
fine-tip heat source as the method of sealing the ends of the cylindrical scaffold to prevent cell 
loss and migration from the device. 
6.4 Limitations in Design Verification 
 There are a number of limitations in the verification of the device that the team 
encountered. First and foremost, the variation and amount of different scaffold thickness samples 
was a limitation in the project. The availability of resources to develop more samples with 
different thicknesses hindered the characterizing of appropriate thickness of the encapsulating 
scaffold. In terms of the cell viability calculations, the sample size of four scaffold images used 
does not provide statistically relevant results, as the sample size is much too small. The team was 
only able to perform two LIVE/DEAD staining procedures, which provided a number of 10x and 
5x images for use. However, the 5x images were unable to be processed with the ImageJ 
software to count the cell nuclei in the images, leaving a smaller amount of 10x images to 
analyze. Further, the use of the fine-tip heat source was not a controlled method of sealing the 
 86 
device. There is room for improvement in the process of sealing the device, as the process should 
be controlled producing uniform results each time of application. Additionally, the Hoechst and 
Phalloidin staining for migration was only performed once on one sample of each thickness due 
to the time constraints of the project and limited availability of Gaudette-Pins wells. 
Furthermore, the lack of availability of cardiomyocytes in the lab prohibited the team from both 
verifying the thickness needed for gap junction formation and verifying the passage of current 
through the bridge. These tests will be recommended for future groups to perform and will be 
discussed further in Chapter 8.  
6.5 Device Impacts 
In terms of the economic impact of the device, the comparison of the cost of electrical 
cardiac pacemakers and the AV node bypass device should be considered. The average electrical 
cardiac pacemaker currently costs $35-45,000 [5], [6]. Based on data provided from the 
Professor Gaudette’s lab and Biosurfaces, Inc., the overall estimated price of developing the AV 
node bypass device would be about $1,500 as shown in Table 7 below. It is important to 
understand that the aforementioned price of the electronic cardiac pacemaker includes the 
manufacturing costs, the sales force costs, and all other associated costs with developing, 
marketing and selling a product. The calculated cost of the AV node bypass device does not 
include these factors. The team believes the AV node bypass device would be competitive with 
the current pricing of pacemakers, but would ideally be cheaper. With the need for less material 
as the device is much smaller than an electrical cardiac pacemaker, it is assumed that the pricing 
of the device would be cheaper.  
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Table 7: Cost of components needed in development of AV node bypass device 
AV Node Bypass Device 
hMSCs $717 (20 million cells) 
Cell Culture Media $270 (2 bottles) 
Trypsin $39 (1 bottle) 
T-Flasks $50 
Fibrin Microthreads $285 (420 threads) 
Cylindrical Scaffold $145 (100 scaffolds) 
Total: $1,506 
 
Ideally, the device would influence society in a positive manner by providing an 
alternative to the current pacemaker. The device would overcome the disadvantages of the 
pacemaker and present society with a better, cheaper option for the treatment of AV nodal block. 
In terms of political ramifications, with this device hypothetically replacing the use of electrical 
cardiac pacemakers, many companies would be affected negatively. The device would ideally 
eliminate the need for the electronic pacemakers, therefore putting certain companies out of a 
product. This may cause negative political ramifications within the medical device industry. 
By eliminating the use of the electrical cardiac pacemaker in the treatment of AV nodal 
block by making use of the AV node bypass device, there would not be a negative impact on the 
environment. Electrical cardiac pacemakers are larger than the AV node bypass device would be. 
Therefore, there would be a decline in the usage of materials for treatment of this disease. There 
is also no need for an outside power source for the AV node bypass device, which will eliminate 
the need for batteries. This will allow for the need to disposing of the batteries to decrease, which 
is better for the environment. Overall, the device would not affect the environment in a negative 
manner. 
 88 
In terms of the ethics of the device, the team foresees no negative impact. The use of 
stem cells is often an ethical concern in society, however this concern often stems from the use 
of embryonic stem cells. These stem cells are obtained from embryos and are often the topics of 
much ethical controversy. However, human mesenchymal stem cells are obtained from adults. 
Therefore, this eliminates the potential negative ethical impact in society.  
The finalized device, after further research and work, would not provide any health or 
safety risks. The PU/PET scaffold has been shown to be biocompatible and would not produce a 
cytotoxic effect in the body. The hMSCs would be contained by the encapsulating scaffold, 
which would prohibit the hMSCs from wandering from the device. Finally, the fibrin 
microthreads have also been shown to be biocompatible and would not produce cytotoxic effects 
once implanted in the body.  
Finally, the manufacturability and sustainability of the final AV node bypass device 
needs to be considered. The manufacturing of the cylindrical scaffold consisting of a pattern of 
different thicknesses may possibly present challenges in the success of the device. Biosurfaces, 
Inc. expressed the challenge of developing such a small cylindrical scaffold through the 
electospinning process. Additionally, a pattern of thick and thin regions may cause even greater 
challenges. In terms of the cell choice, the final device would make use of HCN2 channel 
transfected hMSCs. The availability of these cells and success rate of transfection may present 
challenges in terms of sustainability of the device.  
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Chapter 7: Final Design and Validations 
 
 Upon project analysis, the team developed the final design of the AV node bypass device 
as shown in Figure 33. This device was developed from the initial, straight-line conceptual 
design, due to diameter restrictions presented by the catheter method of implantation. The 
scaffold material used in the device is a PU/PET blend, utilized for its favorable mechanical 
properties. LIVE/DEAD staining performed on hMSCs seeded onto PU/PET scaffold samples 
confirmed the material’s biocompatibility. The scaffold is electrospun at desired thicknesses in 
order to collect, transmit, and deliver current along the length of the seeded microthreads 
contained within the cylindrical scaffold. In terms of catheter implantation, the final design must 
be mechanically stable, as the catheter lead is inserted and snaked through the right, internal 
jugular vein into the right chambers of the heart. In addition, the final design accommodates for a 
fine-tip heat source to be applied to the ends of the scaffold without negatively impacting hMSC 
viability.  
 
Figure 33: Final design with outer thick regions (blue), inner thin regions (pink) and a center thick region (blue) all at least 40-
50 Pm thick. 
 
 As seen is Figure 33, the final scaffold design consists of a thick, electrospun region of at 
least 40-50 Pm in thickness in order to prevent cell migration. This thick, center region is 
composed of small pores that will prohibit cell migration and gap junction formation with native 
cardiomyocytes outside of the scaffold. Gap junctions between hMSCs seeded along this region 
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of fibrin microthreads are responsible for passing current along the length of the bridge. 
However, the absence of gap junctions with native cardiomyocytes along the center of the bridge 
allows for minimal current loss as it is transferred from the atrium to the ventricle. The 
electrospun center contains pores that are large enough to allow nutrients to reach the cells 
contained within this region of the scaffold. 
 The pink regions displayed in Figure 33, are composed of the same electrospun PU/PET 
material as the center region. However, these regions are thinner in order for the hMSCs to form 
gap junctions with native cardiomyocytes located within the heart. Although these regions of the 
scaffold are thinner than the center portion, the thickness must be at least 40-50 Pm in order to 
contain cell migration. Based on the electrospinning fabrication method, the thinner regions of 
the scaffold contain larger pores compared to the center region, allowing for the cells on the end 
of the scaffold to form gap junctions with native cardiomyocytes. When placed within the central 
fibrous body of the heart, one thin region will be located in the right atrium, as gap junctions 
between native cardiomyocytes and seeded hMSCs are needed to collect the electrical current 
produced by the SA node. This second thin region will be located in the ventricle to deliver the 
current through the gap junctions formed between hMSCs and cardiomyocytes located in the 
ventricle. 
 The outer ends of the scaffold are thick, PU/PET material utilized for sealing and 
mechanical stability throughout catheter implantation. These excess, thick regions provide 
surface area on which to apply a fine-tip heat source to shrink the polymer fibers and create a 
seal without negatively impacting cell viability. The sealed ends of the cylindrical scaffold 
prevent hMSC migration from either end of the device. In addition, the thick region is utilized 
throughout catheter delivery, as one thick region is draped over the inner core to absorb the force 
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exerted on the device as it is plunged through the central fibrous body and inserted into the right 
ventricle. The utilization of this thick region throughout delivery is shown is Figure 34. The 
other thick region provides mechanical support as the inner core of the catheter is retracted, 
inserting the opposite end of the device into the right atrium before the catheter is extracted from 
the heart. Similar to the both the center thick region and thinner regions previously described, the 
ends of the scaffold must be at least 40-50 Pm thick in order to prevent cell migration through 
the electrospun pores. 
 
 
 
 
 
 
 
Figure 34: Final design loaded onto specifically designed catheter 
To assemble the AV node bypass device, the PU/PET electrospun scaffold consisting of 
thick and thin regions is manufactured to be a minimum of 2 cm in length and about 1.5-2 mm in 
outer diameter. About 100,000 hMSCs are then seeded onto a 6x fibrin microthread suture, 2 cm 
in length and attached to a straight needle. The suture is inserted into one end of the cylindrical 
scaffold and carefully pulled through. The straight needle is then cut from the suture, leaving the 
seeded thread within the scaffold. Two pairs of forceps are then used to clamp the edges of the 
scaffold. A fine-tip heat source set at about 500-600qF is applied to each end until a seal is 
visually observed. The assembly process of the device is displayed in Figure 35. 
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Figure 35: Assembly Method (left to right, top to bottom); a) hMSC seeded fibrin microthread suture is attached to a straight 
needle b) the suture is inserted and pulled through the cylindrical PU/PET scaffold c) the ends of the scaffold are clamped d) a 
fine-tip heat source is applied. 
 
  
 93 
 
Chapter 8: Conclusions and Recommendations  
  
8.1 Future Testing Recommendations 
Upon the conclusion of the research project, the team identified a number of 
recommendations that should be considered in future work to continue the development of the 
AV node bypass device. The team believes that the completion of these recommended 
fabrication and testing methods is necessary for the successful advancement of the device to the 
clinic.  
8.1.1 Current Flow 
  In order to ensure that the heart is properly paced by the AV nodal bypass bridge, 
voltage stimulation testing should be performed. It is important to ensure that the cells at one end 
of the bridge are beating at the same rate as the cells at the opposite end of the bridge. This 
experiment will ensure that the current stimulated at one end of the bridge is successfully 
collected, carried throughout the bridge and distributed via gap junctions. Cardiomyocytes 
should be seeded onto two coverslips and kept in a 6 well plate with complete medium. A fibrin 
microthread seeded with 100,000 hMSCs should be added into the well with one end of the 
bridge attached to one coverslip, and the other end of the bridge attached to the second coverslip. 
This attachment will allow for gap junctions to form between the hMSCs and cardiomyocytes. 
The cardiomyocytes on one of the coverslips should be electrically stimulated at a specific 
voltage. A reading of the voltage of the second coverslip of cardiomyocytes will be recorded. 
This reading will be compared with the original voltage to determine the ability of the bridge to 
pass the current. This experiment should also be performed with a seeded microthread in the 
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encapsulating scaffold to determine if the overall device is successful in passing the appropriate 
amount of current.  
8.1.2 Mechanical Stability  
The mechanical properties of the material will be important, as the scaffold must possess 
a high degree of elasticity, a high toughness and durability, and a low stiffness to withstand the 
contractile forces and cyclic loading of the heart. To validate the mechanical integrity of the 
device, fatigue testing on the Instron machine should be completed. The scaffold should be 
predisposed to the cyclic loading forces exerted by the heart during contraction.   
8.1.3 Gap Junction Formation  
To examine the ability of the hMSCs within the bypass device to form gap junctions with 
the native cardiomyocytes in the heart, immunohistochemistry (IHC) staining for connexin-43 
(Cx43) should be performed. Cx43 is a protein embedded in hMSC and cardiomyocyte cell 
membranes and are responsible for gap junction formation between cells. In accordance with the 
IHC procedure located in Appendix V, a primary antibody, rabbit-anti-connexin, and a 
secondary antibody, goat anti-rabbit, should be utilized to tag the Cx43 protein for visualization 
during fluorescent microscopy imaging. Theoretically, this will lead to images with a high 
concentration of fluoresced proteins on the edges of adjacent cells. The fluoresced edges will 
illustrate the presence of connexin 43, and therefore gap junctions between the hMSCs within the 
bridge and native cardiomyocytes.  
This test should initially be performed with fibrin microthreads seeded with 100,000 
hMSCs and cardiomyocytes plated in a 12 well plate. Subsequently, this test should be 
performed on the scaffold samples of different thicknesses. Using the Gaudette-Pins wells, 
hMSCs should be seeded on one side of the scaffold, while cardiomyocytes should be seeded on 
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the opposite side. After a pre-determined incubation period, allowing for gap junctions to 
naturally occur between the two cell types, the scaffold should be stained for Cx43 protein and 
accompanying gap junctions between the cells. This test will confirm the optimal scaffold 
thickness needed within the two thinner regions of scaffold, which should all for gap junction 
formation between hMSCs within the device and native cardiomyocytes.  
8.1.4 Physiological Autonomic Responsiveness 
 To ensure the bypass device offers physiological autonomic responsiveness, 
catecholamine stimulation testing should be conducted. Each end of the bypass device should be 
placed within an individual plate of cardiomyocytes and an incubation period should occur. After 
gap junctions have been allowed to form between the hMSCs within the device and the plated 
cardiomyocytes, one end of the bypass device should be stimulated using a catecholamine 
hormone. Epinephrine is one hormone that can be utilized within this procedure, which should 
increase cellular activity. Theoretically, the effects of the stimulus should be observed initially at 
the stimulated end of the bridge and then at the second end of the bridge.  
8.1.5 Delivery Verification 
 Testing must be conducted to evaluate and validate the effectiveness of the chosen 
delivery method, which utilizes a specialized catheter designed by a previous WPI MQP team in 
2011. First, the bypass device must be successfully loaded onto the inner core of the catheter 
device. Following proper loading technique, the catheter delivery should be verified in vivo using 
an animal model. The loaded bypass device should be delivered into a canine heart and the 
catheter should be extracted via the path of insertion. A cross sectional dissection of the canine 
heart should be conducted to assess the mechanical integrity of the implanted bypass device 
throughout insertion. In vivo testing using a canine model is necessary to validate successful 
delivery of the device using the specialized catheter.  
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8.1.5 Conclusions 
 The results of the testing verification methods conducted illustrate the progress made in 
the development of an AV node bypass device utilizing a PU/PET electrospun scaffold and 
hMSCs. Through the LIVE/DEAD staining of hMSCs on scaffold samples, the PU/PET material 
was confirmed to be biocompatible. Migration testing results allowed the team to conclude that 
electrospun scaffold samples of 40μm and 50μm thickness prevent hMSC migration outside of 
the bypass device. Scaffold samples of 20μm thickness allowed for hMSC migration outside of 
the insulating scaffold material. An ideal thickness allowing for gap junction formation between 
hMSCs and native cardiomyocytes should be determined by a future team through the testing of 
various scaffold thicknesses. This testing will determine the ideal thickness for the thinner 
regions of the scaffold. The ideal thickness for the thicker regions should also be determined to 
finalize the device. Finally, the application of a fine-tip heat source at 500°F-600°F successfully 
seals scaffold ends. The method of heat sealing theoretically prevents cell migration outside of 
the ends of the device and maintains cell viability.  
 After speaking to experts in the field, such as Michael Rosen and Ira Cohen, the team 
believes the presented design for an AV node bypass mechanism is a viable option to treat AV 
nodal block. Further research and testing on this device will assist in validating the function of 
the device, eventually bringing the design to the clinic as a replacement for electronic cardiac 
pacemakers.  
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Appendices 
Appendix I: Objectives Tree 
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Appendix II: Pairwise Comparison Charts 
 
Primary PCC: 
  Biocompatible 
Physiologically 
Responsive 
Self-
Sustaining 
Cost-
Effective 
Easy 
to Use Reproducible Deliverable Total 
Biocompatible         
Physiologically 
Responsive         
Self-Sustaining         
Cost-Effective         
Easy to Use         
Reproducible         
Deliverable         
 
Secondary PCCs: 
Biocompatible Immune Response Disruption 
Scar 
Formation Total   
Immune 
Response        
Disruption to 
Contractile 
System        
Scar Formation        
       
Self-Sustaining Nutrients 
Power 
Source Cell Balance Withstand Total  
Nutrients       
Power Source       
Cell Balance       
Withstand 
Loading & 
Forces       
       
Cost-Effective Manufacturing Insurance Patient Surgeon Hospital Total 
Manufacturing       
Insurance       
Patient        
Surgeon       
Hospital       
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Reproducible - 
Accuracy Mechanical Electrical Biological Total   
Mechanical       
Electrical       
Biological       
       
Deliverable Compatible 
Minimally 
Invasive Implantable Total   
Compatible       
Minimally 
Invasive       
Implantable       
 
 107 
 
Appendix III: LIVE/DEAD Staining Protocol 
 
Preparation for staining on scaffold: 
1. Cut scaffold samples and place into a well plate  
2. Sterilize scaffold samples in the well plate via ethylene oxide treatment 
3. After de-gassing period, add complete medium to the wells with scaffolds 
4. Seed scaffold samples with approximately 40,000 hMSCs by pipetting cell suspension 
directly onto the scaffolds 
5. Seed 40,000 hMSCs into one of the wells in the well plate to be a dead control 
6. Incubate samples for 1 and 4 days 
7. Follow procedure below after 1 and 4 days 
 
Reagents: 
Solution 1: 
1. 1.0mL Serum Free DMEM 
2. 1.0µL Ethidium Homodimer-1  
3. 1.0µL Calcein AM 
 
Solution 2: 
1. 1.0mL Serum Free DMEM 
2. 1.0µL Ethidium Homodimer-1  
3. 1.0µL Calcein AM  
4. 0.5µL Hoechst Dye 
 
Procedure: 
1. Incubate dead controls in 70% Ethanol for 30 minutes prior to experiment 
2. Mix solution 1 within 1 hour of use 
3. Incubate cells with solution 1 for 15 minutes 
4. Mix solution 2 within 1 hour of use 
5. Incubate cells in solution 2 for 15 minutes 
6. Wash cells with 1x PBS 3 times 
7. Fix cells in 4% Phosphate buffered formaldehyde for 10 minutes 
8. Mount scaffold on coverslip and image 
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Appendix IV: Hoechst and Phalloidin Staining Protocol  
 
Preparation for Scaffold Staining: 
1. Cut scaffold samples to the size of the Gaudette-Pins well 
2. Sterilize the sample/well with ethylene oxide treatment 
3. Place Gaudette-Pins with scaffold onto 6 well plate with complete media 
4. Seed scaffold sample in the Gaudette-Pins well with 80,000 hMSCs by pipetting cell 
suspension directly onto the scaffold 
5. Incubate samples for (at least) 4 days 
6. Follow Procedure below 
 
Reagents: 
1. DPBS 
2. 4% paraformaldehyde 
3. 0.25% Triton-X 
4. 1% BSA 
5. Phalloidin  
6. Hoechst 
 
Procedure:  
1. Aspirate media 
2. Rinse with DPBS x2 
3. Fix in 4% paraformaldehyde for 10 minutes 
4. Rinse with DPBS x2  
5. Remove scaffold from Gaudette/Pins well and place in 6 well plate 
6. Block with BSA solution for 30 minutes 
7. Phalloidin solution for 30 minutes 
8. Rinse with DPBS x2 
9. Hoechst solution for 3-5 minutes 
10. Rinse with DPBS x2 
11. Mount scaffold on coverslip and image 
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Appendix V: Immunohistochemistry Cx43 Staining Protocol 
 
Preparation for IHC Staining: 
1. Obtain 6x thread bundle (or a variation of bundle) 
2. Cut into 2-3 cm sutures 
3. Quantum Dot Load 100,000 hMSCs 
4. Seed with 100,000 hMSCs on for 24 hours 
5. Incubate seeded threads for a minimum of 48 hours in complete media 
6. Aspirate media and remove seeded thread from tissue culture plate  
7. Place seeded thread into 6, 12 or 24 well plate containing neonatal rat cardiomyocytes 
8. Incubate for an appropriate period of time  
9. Seed an appropriate amount of hMSCs onto a separate tissue culture dish/well containing 
neonatal rat cardiomyocytes. Incubate for an appropriate period of time 
10. Follow Staining Procedure Below 
 
Reagents: 
1. Cold acetone  
2. 5% Normal Goat (or Rabbit) Serum in PBS 
3. Primary antibody: mouse anti-connexin (or anti-alpha actinin) 1:100 in 5% NGS (or 
NRS) 
4. Secondary antibody: goat (or rabbit) anti-mouse Alexa Fluor 546 1:400 in 5% NGS (or 
NRS) 
5. Hoechst stain: 
a. 0.0167% Hoechst dye in PBS 
b. 0.5µL in 3000µL PBS 
6. 0.25% Triton X-100 
7. Phalloidin (AF 488 Phalloidin)  
 
Procedure: 
1. Fix cells with paraformaldehyde for 10 minutes at room temperature 
2. 3 washes in PBS (5 minutes each) 
3. Place samples in cold acetone - place in freezer at -20 degrees Celcius for 10 minutes 
4. 3 washes in PBS (5 minutes each) 
5. 0.25% Triton X-100 – 10 minutes 
6. Block with 5% Normal Goat (or rabbit) Serum for 45 minutes 
a. 400microliters of 100% goat serum in 8mL of PBS 
7. Leave goat (or rabbit) serum on negative sample, aspirate off the positive sample 
8. Primary mouse anti-connexin (and/or anti-alphaactinin) added only to positive sample in 
cold room - leave overnight in refrigerator 
a. 2microliters primary in 200microliters PBS 
9. 3 washes in PBS (5 minutes each) 
10. Secondary goat (or rabbit) anti-mouse Alexa Fluor 546 AND the phalloidin solution 
added to both samples, left for 1 hour in the dark 
11. 3 washes in PBS (5 minutes each with lid closed) 
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12. Hoechst stain - 0.5microliters Hoechst in 3000microliters PBS (left for 5 minutes with lid 
closed) 
13. 3 washes in PBS (5 minutes each with lid closed) 
14. Put coverslip on tissue sample slide 
a. Get water off, drop cytoseal, make sure no air bubbles 
15. Image 
 
